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The modern rational drug discovery process starts with the hypothesis that 
modulation of certain targets may exert therapeutic value and therapeutics directed 
at those targets are then developed to combat diseases. In this big data era, the large 
and complex collection of various targeted therapeutics data call for efficient data 
management and analysis methods. The development of databases to curate, store, 
integrate and retrieve data and methods to analyze and visualize data are of 
importance and practical use to increase the success rate of drug discovery. 
 
This work starts with the update of the Therapeutic Target Database (TTD), which 
serves as a comprehensive, reliable and integrated information source of 
therapeutics data, including drug targets, drug molecules, natural products and 
biomarkers. The search tools implemented by the International Classification of 
Disease (ICD) codes were added to link and retrieve the target, biomarker and drug 
information. Biomarker information was newly added to the TTD and the data 
contents were significantly expanded. The updated TTD database enables more 
convenient data access and will facilitate the discovery, investigation, application, 
monitoring and management of targeted therapeutics.  
 
An important strategy in targeted therapeutics is the use of multi-target therapeutics 
such as multi-target drugs and drug combinations, which are more efficacious and 
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less prone to resistance than single-target drugs for heterogenetic diseases like 
cancer. To facilitate the multi-target drug discovery, bioinformatics methods such as 
machine learning methods to predict multi-target inhibitors, clustering method to 
look for drug prolific regions and properties and systematic analysis of synergistic 
natural product combinations were developed based on the information from TTD.  
 
Three machine learning methods, support vector machine (SVM), K-Nearest 
Neighbor( kNN) and probabilistic neural network (PNN) were developed as virtual 
screening tools to predict dual-target inhibitors from large chemical libraries. 
Models of 29 targets pairs with varying similarity levels between their drug-binding 
domains were developed and showed good performance with reasonably high yields 
and low false hit rates. But the target selectivity performance of these VS tools needs 
improvement. In search of clues to further modify the virtual hits for drug 
development, a hierarchical clustering method was proposed to cluster known drugs 
in the chemical space. Preliminary investigation seemed to hint some drug prolific 
regions and properties.  
 
Moreover, natural product combinations was systematically analyzed to learn novel 
multi-target mechanisms. And it was found that most of the evaluated natural 
products and combinations are sub-potent to drugs. Sub-potent natural products can 
be assembled into combinations of drug level potency, though at relatively low 
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probabilities. Distinguished multi-target modes were identified and could shed light 
to the design of multi-target therapeutics. 
 
In view of the current shift of drug development focus to more personalized targeted 
therapeutics, the collected comprehensive set of biomarkers and the relevant 
information were systematically analyzed. The analysis of current biomarkers in 
TTD with respect to ICD disease classifications suggested that biomarker (especially 
multi-marker), target and drug information may be incorporated into revised ICD 
codes for coding disease subclasses and refining patient and drug-response 
sub-populations for personalized treatment. In addition, the feasibility of utilizing 
non-invasive biomarkers for mobile health applications was discussed. 
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Chapter 1: Introduction 
1.1 Overview of targeted therapeutics in modern drug 
discovery  
 
From ancient mysterious herbs to modern synthetic chemicals, drugs have been an 
integral part in people's health and well-being. It is for the benefit of the whole 
society to discover new drugs in the hope of defeating diseases and guarding health.   
 
Because of the natural high demand for new drugs, abundant economic opportunities 
exist in the field of pharmaceutical industry. Especially in recent years, with the 
rapid development of biological technologies and huge advance in combinatorial 
chemistry, the drug discovery in pharmaceutical industry has received roaring 
attention and showed promising future. A tremendous amount of money, time and 
human resources have been injected into drug discovery, in the hope of finding new 
drugs. Statistics show that R&D expenditures in pharmaceutical industry has been 
growing at an annual growth of 13%  since 1970, which leads to a total 50-fold 
increase and reaches 13% of the revenues of pharmaceutical companies. (1) And it is 
estimated that it would take 12-15 years, one billion US dollars on average in order 
to discover a new drug. (2)  
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A review of modern drug design stages will help to understand the lengthy and 
costly process to bring a new drug into market. As illustrated in Figure 1.1, the 
modern rational drug discovery starts with the identification of drug targets, by 
modulating which may result in desirable therapeutic effects to cure diseases or 
alleviate pain.  
 
 
Figure 1. 1 Modern drug discovery process 
This rational approach is in great contrast with traditional drug discovery, which 
mainly relies on “trial and error” approach or serendipitous discovery. Thanks to the 
advance in analytical chemistry and improvement of purification techniques in the 
early 20
th
 century, active ingredients from traditional remedies and medicinal plants 
were characterized and some were extracted as drugs. Historically in classical 
pharmacology, collection of natural products, extracts and synthetic small molecules 
were screened against cell lines or organisms so as to identify the therapeutic 
chemicals. Later, with the advance of biochemistry that expanded people‟s 
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understanding of diseases at the molecular level, it became clear that the therapeutic 
effects of many drugs came from their interactions with the biological molecules 
such as nucleic acids and proteins (like receptors, enzymes, ion channels, structural 
and transport proteins). And the modulation of such biological molecules, known as 
drug targets, can then result in desirable therapeutic effects. 
 
Hence, the modern rational drug discovery is based on the hypothesis that 
modulation of certain targets may exert therapeutic effects and drugs directed at 
these targets are developed subsequently. A deep understanding of disease 
mechanism and molecular players within the disease pathology is required for target 
identification, but it is not sufficient to just identify the possible targets. Target 
validation is an important follow-on step to make certain that a potential target 
indeed plays a critical role in disease.  
 
The purpose of target validation is to confirm the functions of potential targets and 
compounds modulating those targets will lead to therapeutic effects (3, 4). The target 
needs to be validated in various cell-based and animal disease models to establish 
and confirm its essential role in disease. (3, 5). Genetic methods, such as gene 
knockout and RNA interference, are commonly applied to conduct in vivo target 
validation (5, 6).  
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After target discovery, the following step of lead discovery starts with lead 
identification.(7, 8) A lead compound is a potentially therapeutically useful chemical 
which has pharmacological activity but requires structure modifications in order to 
become drug.(9) An assay to test the potency of compounds against the target needs 
to be developed and large chemical libraries of small molecules can then be screened 
using the developed assay. With the advance in automation systems, high throughput 
screening techniques have been applied extensively to rapidly test the activities of 
chemicals against the target. The emergence of combinatory chemistry renders it 
possible to conduct systematic screening of a large number of small molecules with 
the maximized structure diversity. (10-12) 
 
The leads identified from screening processes needs further evaluation on their 
potency, off-target activities and physiochemical or metabolic properties. Certain 
compound clusters with good pharmacological properties will be selected for 
modification before going into pre-clinical research stage when experiments on 
animal models are done to test the safety and efficacy profiles. 
 
If everything goes well, the lead compounds will finally enter clinical trials and be 
tested on human beings. In recent years, the drug discovery process normally lasts 
for 12-15 years and the total discovery and development cost of a new drug is 
estimated to be as enormous as one billion US dollars.(2) Around half of the drug 
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development time and nearly two thirds of the cost needed for a new drug to gain 
FDA approval are devoted to clinical trials. (13) Overall, the phase I, phase II and 
phase III clinical trials are the most costly and time-consuming steps in the drug 
development processes. And the success of clinical trials relies heavily on the 
careful selection and strategic modification of lead compounds from previous steps.  
  
In sum, the modern drug discovery, reliant on the biological insights of diseases, 
starts with the identification and validation of targets and then therapeutics directed 
to the targets are screened, optimized and selected to enter clinical trials. The 
targeted therapeutics are usually rationally designed drugs with promising efficacy 
profiles and few toxic effects. This is particularly true for cancer treatment. In the 
past, the standard treatment for cancer was the non-specific cytotoxic chemotherapy, 
which worked primarily through the inhibition of cell division and killed rapidly 
dividing cells in both cancer cells and human normal tissues. The past two decades 
see a dramatic shift of cancer drug development focus from the traditional cytotoxic 
chemotherapy to molecularly targeted therapeutics. The mechanisms of action and 
toxicity profiles of molecularly targeted drugs are different from traditional 
cytotoxic chemotherapy. The targeted cancer therapeutics interfere with specific 
molecular targets essential for tumor development and growth. Because such 
molecular targets are usually overexpressed or mutated in the cancer cells only, the 
targeted therapeutics are generally better tolerated in cancer patients than the 
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traditional cytotoxic chemotherapy. (14, 15)   
 
1.2 The importance of multi-target therapeutics  
However, a large percentage of drugs in development, which are typically directed at 
an individual target, sometimes show reduced efficacies and undesired safety and 
resistance profiles. For multigenic diseases, such as cancer, or diseases that act on 
different tissues or cell types, multi-target therapeutics can be more efficacious and 
less prone to resistance, compared to those drugs designed to act against an 
individual molecular target (16). Multi-target drugs, which are single chemical 
entities that act simultaneously at multiple molecular targets, and drug combinations, 
which are formulations of multiple active ingredients mixed in a single dosage form, 
are multi-target therapeutics studied in this thesis. 
  
Multi-target therapeutics against selected multiple targets can selectively modulate 
the elements of those countertarget and toxicity activities, thus achieving enhanced 
therapeutic efficacies and improved safety and resistance profile. In particular, 
multi-target agents are able to regulate network robustness(17), redundancy(18), 
crosstalk(19), compensatory and neutralizing actions(20), anti-target and 
counter-target activities(21), and on-target and off-target toxicities(22). 
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Multi-target drugs tend to be more sparsely distributed in the chemical space than 
individual-target agents. For instance, known dual kinase inhibitors of selected 
kinase pairs are typically 10-fold smaller in numbers than the known individual 
kinase inhibitors (23). Therefore, exploration of larger chemical libraries may be 
needed for discovering new multi-target hits, particularly novel ones, against 
selected targets. To facilitate drug discovery, efficient methods to predict 
multi-target agents are highly desired.  
 
Drug combinations are already standard treatments of many diseases including 
cancer, diabetes, viral and bacterial infections. And the high efficacy of existing 
drug combinations shows that searches to identify multi-target mechanisms can shed 
new light in drug discovery. Bioinformatics approaches to collect relevant drug 
combination data from literature and to analyse the pathways and molecular 
interaction profiles involved in drug combinations are expected to be useful. 
 
1.3 More personalized targeted therapeutics driven by 
biomarkers 
Modern drug development has been primarily focused on targeted therapeutics. 
(24-26) In recent year, there is an increasing movement towards stratified and 
personalized medicines.(27-29) Extensive efforts from the research, industry, 
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clinical, regulatory and management communities and the chemistry, biology, 
pharmaceutics, and medicine disciplines have been collectively directed at the 
discovery, investigation, application, monitoring and management of targeted 
therapeutics and the diagnostic and prognostic biomarkers.(27, 30-33)  
 
According to National Institute of Health (NIH), a biomarker is defined to be “a 
characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to 
therapeutic intervention”.(34) It can be a naturally occurring molecule, gene, or 
characteristic, which marks a physiological process or disease. Biomarkers can be 
used to support new medical diagnostics, preventive medicine, and drug 
development. The major disease related biomarkers are used to recognize an overt 
disease (diagnostic biomarkers) and to predict the disease progression (prognostic 
biomarker). Most relevant to drug discovery are the drug related theragnostic 
biomarkers that serve to guide treatment in various diseases. These theragnostic 
biomarkers can indicate the optimal dosage for a particular patient, or how the drug 
is metabolized in the body , or if the patient will be responsive to a certain drug 
treatment.  
 
The clinical trial phases in modern drug discovery usually adopt a “one size fits all” 
approach and try to define the best treatment for the average patient in the whole 
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population. But it has been argued that such an approach may not be the most 
effective method for drug discovery.(35) The best treatment for an average patient 
may not be the optimal treatment option for a particular patient due to the 
heterogeneity of their molecular makeups among the patients. The use of biomarkers 
early in the drug development phase to select the likely responsive patients may help 
lower the attrition rate of clinical trials that results from patient heterogeneity in 
complex diseases like cancer. Only patients that are predicted to be responsive to a 
certain drug treatment will receive the drug in the clinical trials, thus decreasing the 
toxic effects and costs associated with the patients receiving ineffective treatments. 
As a result, the stratification of patients by companion biomarkers of a drug 
treatment will increase the success rate of clinical trials, accelerate the drug approval 
and provide the personalized treatment options.  
 
In sum, the knowledge of the biomarkers will be useful not only for the discovery 
and development of targeted therapeutics and biomarkers (36, 37), but also for 
facilitating the development and practice of the diagnosis, prescription, monitoring 
and management of patient care in stratified and personalized medicines (27, 38, 
39).   
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1.4 Bioinformatics methods for analysis of targeted 
therapeutics 
The unprecedented development of technological advances and rapid accumulation 
of knowledge and information in biology and medicine through all fields of the 
“-omics” and translational researches signal the big data era of pharmaceutical 
information. The pharmaceutical industry is in dire need of an open-source, easily 
accessible, reliable and well-integrated data source. The large and complex 
collection of various targeted therapeutics data require effort to construct databases 
that can store, integrate and retrieve reliable information. Moreover, the known 
targeted therapeutics data in literature also call for bioinformatics analysis methods, 
which are of importance and practical usage to drug discovery.   
 
1.4.1 The update of therapeutic target database to serve as 
an integrated information platform of targeted therapeutics 
Drug discovery efforts can be facilitated by the information of drugs, targets, 
multi-target agents, drug combinations and biomarkers. Hence, to construct a database 
that provide such information will be a meaningful attempt. 
 
Therapeutic Target Database (TTD, http://bidd.nus.edu.sg/group/ttd/ttd.asp) has been 
developed to provide comprehensive information about efficacy targets and the 
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corresponding approved, clinical trial and investigational drugs. The information of 
therapeutic targets and the targeted therapeutics included in TTD will facilitate target 
and drug discovery. 
 
The aim of updating TTD is to make it into a more useful target and drug discovery 
resource in complement to other related databases such as drugbank (40). Continuous 
efforts have been made to provide the latest and comprehensive information about the 
targets, drugs and other therapeutics in different development and clinical stages, 
which is highly useful for focused drug discovery efforts and pharmaceutical 
investigations against the most relevant and proven targets. (24, 41) In addition to the 
update of these databases by expanded target and drug data contents, the usefulness of 
these databases for facilitating drug discovery efforts has been further enhanced by 
adding additional information and knowledge derived from the target and drug 
discovery processes.  
 
Besides being a useful tool to store, retrieve and organize data, TTD serves an 
essential information platform for analyzing the data. Valuable information contained 
in the known drugs, targets, multi-target agents, drug combinations and biomarkers 
can be learnt through various bioinformatics analysis approaches. Many problems 
limiting drug discovery development can be addressed by such analysis and 
information learnt from the data in TTD will facilitate targeted therapeutics. The 
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procedures of this work will be the foundation of this thesis and will be discussed in 
detail in chapter 2. 
 
To facilitate the modern drug discovery, various bioinformatics methods to analyze 
the targeted therapeutics based on the information from TTD have been developed 
and will be introduced in the following sections. 
 
1.4.2 Machine learning methods to predict multi-target 
agents from large chemical libraries  
The importance of multi-target agents for treatment of complex diseases and the 
difficulty to predict them due to their limited number have been introduced in 
chapter 1.2. In this thesis an efficient virtual screening method to predict multi-target 
agents will be presented to address the problem. It is therefore necessary to give an 
overview of virtual screening. 
 
In the lead discovery of rational drug design process, although the high throughput 
screening techniques significantly reduce the time and cost consumed for screening 
an individual compound (28), the daunting size of combinational chemical library is 
beyond the capability of wet-lab experimentations.   
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To solve the problem, various virtual screening techniques has been developed in 
recent years to help accelerate the lead discovery and make it more efficient (18-24). 
Two different strategies are used in virtual screening, namely structure-based and 
ligand-based.  
 
If the 3D structure of a validated therapeutic target is known, a structure-based 
virtual screening technique such as docking can be used to estimate the possibility of 
good binding affinity between the compound and the target. Through molecular 
modeling calculations, a scoring function could be applied to give a score to indicate 
the possibility. 
 
Given a set of compounds with known structures that bind to the target, a 
ligand-based virtual screening approach could be used. Chemical structure similarity 
search, pharmacophore models that capture the information shared by the known 
ligands, machine learning models to learn from known structures and generate rules 
to describe substructure features or physiochemical features, quantitative structure 
activity relationship models that correlate the activities and quantitative structure 
properties of ligands are popular approaches in ligand-based virtual screening.  
 
In-silico methods mentioned above have been extensively explored as virtual 
screening (VS) tools for facilitating the discovery of multi-target agents from both 
Chapter 1: Introduction 
14 
 
focused and large chemical libraries.(23, 42-47) One popular strategy in searching 
multi-target agents is to combinatorially use individual-target VS tools to separately 
screen chemical libraries against each of a group of selected multiple targets for 
finding virtual hits active against all of the selected targets.(45) 
 
The level of success in screening larger chemical libraries depends on the ability of 
VS tools to produce sufficiently high hit retrieval rates (yields) and low false hit 
rates. (23, 45) High yields against individual target compensate for the reduced 
collective yields against multiple targets (if the yield for one target is 50∼70%, the 
collective yield for two targets may be statistically reduced to 25∼49%). Low false 
hit rates ensure that virtual hits are sufficiently enriched with true multi-target agents 
(i.e. sufficient percentage of virtual hits are true hits). Multi-target VS performance 
may also be affected by the similarity level of the drug-binding domains of the 
selected multiple targets. For multiple targets of higher similarity levels, it may be 
harder to distinguish multi-target agents from individual-target agents, because of 
the smaller differences between their structures. Likewise, inhibitors of other similar 
targets may also be falsely recognized as multi-target agents of selected multiple 
targets because of binding site similarity between the other similar target and one or 
more of the multiple targets of the multi-target agents. 
 
Therefore, VS methods for screening multi-target agents need to be rigorously 
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evaluated not only on the yield of multi-target hits but also on target selectivity 
(ability to distinguish multi-target agents from individual-target agents and agents of 
similar targets). Ligand based machine learning methods such as combinatorial 
support vector machines (Combi-SVM) have recently been explored as VS tools for 
searching dual kinase inhibitors and dual target serotonin reuptake inhibitors from 
large compound libraries.(23) The machine learning methods work well in 
predicting serotonin reuptake inhibitors with fair yields, moderate to good target 
selectivity and low false hit rates. More comprehensive tests against diverse sets of 
target pairs of different biochemical classes and varying similarity levels are needed 
to fully evaluate the potential of these and other VS methods in searching 
multi-target agents.  
1.4.3 Clustering method to analyse the distribution patterns 
of targeted drugs in target-specific chemical space 
Using machine learning methods, virtual multi-target hits could be identified from 
large chemical databases. A small percentage of virtual hits validated by wet-lab 
experiments will enter the next phase of drug discovery. From hit to lead to clinical 
trial drugs and to approved drugs, the drug discovery process is still time and money 
consuming (48) and methods to identify drug candidates are desired.  
 
Out of the many compounds that pass virtual screening and subsequent experimental 
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validation to be identified as leads, few of them could pass clinical trial phase and 
enter the market. According to a number of reports (1, 49) , the drug failure rate 
during clinical trials have increased significantly, with an estimation as high as 90% 
(50).   
 
Myriad of reasons are behind the high drug failure rate. Problems such as poor 
bioavailability (39% of failures), low clinical efficacy (30% of failures), toxicity 
(11%) and adverse reactions in humans (10%) have been reported as the major 
causes for failure.(50) Other than these, commercial reasons, formulation issues and 
so on also contribute to the high attrition rate. (51) 
 
All these problems become more frequent in recent years, mostly because of the 
advent of combinatorial chemistry. The evolutionary invention of high-throughput 
screening (HTS) has generated a very large number of potential drugs. Traditionally, 
the most important criterion for selecting the compounds to synthesize for HTS was 
to increase the chemical diversity of the structure. However, other qualities that 
finally influence whether a compound would pass the clinical trials, like efficacy, 
toxicity, bioavailability and so on, were largely ignored.(52) Hence, since the 
introduction of combinatorial chemistry, this neglect has led to a shift in those 
quality profiles of compound libraries available for drug development, which in turn 
negatively affects the efficacy of HTS screened compounds that will proceed into 
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the clinical phases.(53)   
 
More clues to drugs can be obtained from the distribution profiles of approved and 
clinical-trial drugs. Using the clustering method, the large chemical space could be 
explored and areas where drugs are more likely to come from could be found. 
 
Restricted by the structure conformation of targets, hits of a certain target generally 
adopt several specific scaffolds. The approved and clinical trial drugs are composed 
of a limited number of molecular scaffolds (54-56) in contrast to the high number of 
bioactive molecular scaffolds (57, 58). For instance, many drugs have been derived 
from individual scaffold groups such as macrocycles (59), and 12 FDA approved 
anticancer kinase inhibitor drugs (60, 61) are grouped into three scaffold groups (62). 
Investigation and exploration of these highly privileged drug scaffolds are important 
for discovering new drug-like scaffolds, molecular analogs and new drugs. From 
hits to leads to final clinical phases, the potential for drug development of a hit 
depends not only on its bioactivity, but also on the properties of its structures, such 
as optimized drug-likeness(63) and minimized unwanted properties (64, 65). 
 
Questions arise as to whether drugs of a target tend to cluster together in the 
chemical space and whether the scaffolds of hits in those drug-clustered areas are 
more likely to be drug productive. Through clustering drugs, inhibitors and similar 
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compounds of a certain target, the above questions could be investigated and 
possibly answered. 
 
In sum, we expect that insights obtained from clustering patterns will give more 
clues to the drug development. But due to the limit in time and computational power 
and the huge amount of data to cluster in order to analyze the patterns, only 
preliminary results will be outlined in chapter 3 part 2. 
 
1.4.4 Systematic analysis to study synergistic combinations 
of natural products as potential sources of multi-targeted 
therapeutics 
Partly because of low drug productivity from high-throughput screening and 
combinatorial chemistry based drug discovery programs, there have been renewed 
interests in the exploration of natural products (NP) as sources of new drugs (60-62, 
66-69). In particular, NP combinations, in many cases as combinations of whole 
herbs or herbal extracts, have been extensively studied (70, 71), tested in clinical 
trials (72-74), and widely used in traditional, folk and alternative medicines (75, 76). 
These NP combinations may be useful sources for developing new drug 
combinations based on their novel multi-targeted mechanisms (16, 73, 77) or 
molecular scaffolds (58) to meet the increasing demand for multi-targeted drug 





Opinions vary regarding to the therapeutic efficacies of NP combinations. One 
attributes the efficacies of NP combinations to placebo effects (79-81) based on 
some indications from clinical trials (80, 81) and the findings that many bioactive 
NPs are sub-potent with respect to drugs (82, 83). Another credits the efficacies of 
NP combinations to synergistic effects (71, 73, 82, 84-86) based on the findings that 
some NP combinations produce significantly better effects than equivalent doses of 
their components (82, 85)and clinical outcomes are not necessarily influenced by 
positive beliefs (79).  
 
The contribution of synergistic effects to therapeutic efficacies has been extensively 
studied (71, 73, 85, 86). While many studies have consistently suggested that 
therapeutic potency can be enhanced by synergistic effects, the levels of potency 
enhancement, particularly with respect to those of drugs, have not been 
systematically studied to quantitatively assess the contribution of synergism to the 
therapeutic efficacies of NP combinations. 
 
The potency difference between natural products and drugs, the feasibility and 
molecular basis to recover the difference by synergistic combination will be 
addressed in chapter 4.   




1.4.5 Analysis of biomarker for personalized medicine 
The information of targeted therapeutics and biomarkers may be potentially 
incorporated into the widely-used disease classification systems for more refined 
classification of disease subclasses and patient subpopulations responsive to a 
particular treatment so as to better facilitate the diagnosis, prescription, monitoring 
and management of patient care in stratified and personalized medicines. While the 
information about targeted therapeutics and biomarkers can be obtained from the 
established drug (87), efficacy target (88) and biomarker (89-91) databases, the data 
access modes of these database are not specifically designed for optimally 
supporting such tasks. There is a need to introduce new access modes based on such 
widely-used disease classification systems as the International Classification of 
Diseases (ICD) codes developed by the World Health Organization (WHO) (92, 93).  
These new access modes also enable broader, more convenient and automatic data 
access, processing and exchange by all bench-to-clinic communities particularly 
non-domain experts. By analyzing TTD biomarker information, this new access 
mode will be elaborated in chapter 4.1. 
 
A high level of interest in mobile health (mhealth) has emerged recently, as 
exemplified by the US Secretary of Health and Human Services Kathleen Sebelius‟ 
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reference of mHealth as “the biggest technology breakthrough of our time” and its 
use as being able to “address our greatest national challenge.” A Pubmed keyword 
search using “mhealth” showed 245 publications in 2012-2014 compared to only 41 
publications before 2012.  
 
Increasing efforts have been directed at the development of molecular biomarkers 
and the new detection technologies into mhealth devices to extend the coverage and 
improve quality of the mhealth. But there are questions about whether molecular 
biomarkers combined with the new technologies are ready for mhealth applications: 
(1) whether the new technologies are sufficiently sensitive, fast and inexpensive for 
biomarker detection, (2) the relevance and accuracies of the literature-reported 
non-invasive molecular biomarkers for mhealth applications, (3) how the healthcare 
providers cope with the increased workload resulting from widespread use of 
mhealth devices. 
 
These questions can be addressed by analyzing the literature-reported biomarker 
detection capability (detection sensitivity, required sample volume, testing time, and 
cost) of the new technologies, and the relevance (disease coverage, patient 
populations) and diagnostic/prognostic accuracies of the 664 literature-reported 
non-invasive molecular biomarkers stored in TTD for mhealth applications. As a 
byproduct, the feasibility and potential issues of workload reduction by developing 
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and using a digitally-coded biomarker, disease and therapeutic information 
processing system for electronically pre-screening the mhealth biomarker readings 
will be discussed in chapter 4.2. 
 
1.5: Outline of thesis 
 
The main body of this thesis starts with the update of Therapeutic Target Database 
(TTD) in Chapter 2 as a meaningful effort to curate, store, integrate and retrieve data 
of various types of targeted therapeutics, including drug targets, drug chemicals, 
natural products and biomarkers. The drug and target information stored in TTD was 
updated constantly to include recent approvals into clinical trials and markets, new 
categories of information such as multi-target drugs and drug combinations were 
added to TTD in the last update and the most recent update incorporated the 
biomarker information and linking of all data through international classification of 
disease code. Through these updates, TTD serves as a comprehensive and integrated 
information source of targeted therapeutics to facilitate drug discovery. And various 
bioinformatics methods based on data from TTD were developed and discussed in 
subsequent chapters. 
 
Chapter 3 describes several methods to facilitate the design of traditional 
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multi-target small molecule drugs. Three machine learning methods, support vector 
machine (SVM), K-Nearest Neighbor( kNN) and probabilistic neural network (PNN) 
were implemented as virtual screening tools to predict dual target inhibitors from 
large chemical libraries such as MDDR and pubchem. Models of 29 targets pairs 
with varying similarity levels between their drug-binding domains were developed. 
And the multi-target hit and target selection performances of the combinatorial SVM, 
KNN and PNN were evaluated in detail in Chapter 3.1.  
 
Using machine learning methods, virtual hits could be identified, but from hit to lead 
and from lead to drugs, methods were still in demand to identify compounds of good 
structure scaffold and optimal drug property that could have higher chance to enter 
clinical trials and become drugs. In chapter 3.2, a hierarchical clustering method was 
developed to cluster drugs, inhibitors of a specific target in the chemical space 
spanned by structurally similar bioactive and non-bioacitive compounds. 
Preliminary investigation of the plausible drug distribution patterns in the chemical 
space is outlined in hope to give more clues to drug development. 
 
Partly due to the low productivity of virtual screening and synthetic chemistry, 
interests in natural product has been renewed. In particular, the natural product 
combinations may be useful sources for developing new drug combinations based 
on their novel multi-target mechanisms or molecular scaffolds. In chapter 4, a 
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systematic analysis of synergistic natural product combinations was described. The 
potency difference between natural products and drugs, the feasibility and molecular 
basis to recover the difference through synergistic combinations are addressed and 
specific multi-target modes are identified. 
 
Chapter 5 is devoted to reflect the current shift of drug development focus to more 
personalised targeted therapeutics. Current biomarkers in TTD will be analyzed with 
respect to disease subtype classifications. More refined classification of patient 
subpopulations for personalized targeted therapeutics will be proposed. In addition, 
the feasibility of utilizing non-invasive biomarkers for mHealth applications are 
analyzed and discussed.  
 
The last chapter 6 summarises all the major findings and merits from the research 
works described in the previous chapters and future works to further develop the 
targeted therapeutics are described.
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Chapter 2 Update of therapeutic target database as an integrated 
source of targeted therapeutics data 
Therapeutic Target Database, first developed in 2002, has been in the frontier to 
provide reliable information about therapeutic targets. In the past decade with rapid 
progress in target discovery, TTD still remained one of the most popular and mostly 
accessible database to provide pharmaceutical information on therapeutic targets. 
Drugs that act on novel targets have been approved or entered clinical trials, and 
new pharmaceutical information regarding drugs and therapeutic targets have 
emerged. To keep the data in pace with the current drug discovery progress, it is of 
great importance to update the data in TTD. And not only should information 
regarding drugs and drug targets be updated, but also other relevant information 
about other therapeutics such as multi-target agents, natural products and biomarkers 
should be incorporated in the database.  
 
In this chapter, the details of the updates to TTD will be explained, with the focus on 
the collection and access of data. And the data in TTD act as the foundation of the 
work described in the subsequent chapters. Hence, various aspects of data in TTD 
will be elaborated, but the construction of TTD database such as design and 
imprementation of this relational database will be skipped from this thesis, as the 
update of TTD was a collective effort and my work was mainly on the collection and 
curation of data. 
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2.1 Statistics of updated targeted therapeutics in TTD 
Major improvements were made to the Therapeutic Target Database (TTD, 
http://bidd.nus.edu.sg/group/ttd/ttd.asp) to facilitate target-oriented drug discovery in 
the past two updates (2012 update and 2014 update).   
 
As a popular publicly accessible database that provides comprehensive information 
of targets an drugs, the target and drug data in TTD were significantly expanded to 
its current status of 388 successful, 461 clinical trial, and 1,467 research targets; 
2003 approved (1,008 nature product derived), 3,147 clinical trial, 498 discontinued 
clinical trial and 14,856 experimental drugs. These are compared to the 364 
successful, 286 clinical trial, and 1,331 research targets; 1,540 approved (939 natural 
product derived), 1,423 clinical trial, 345 discontinued clinical trial and 14,853 
experimental drugs in the 2012 update of TTD and the 348 successful, 249 clinical 
trial, 43 discontinued clinical trial and 1254 research targets, and 1514 approved, 
1212 clinical trial and 2302 experimental drugs. Newly approved drugs and targets 
were constantly kept track of and deposited into the database, as well as novel drug 
molecules that recently entered the clinical trials. There was a tremendous increase 
of the number of experimental drugs included in TTD over the past few years so as 
to make TTD a comprehensive source of drug information.  
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Other than drugs and targets, multi-target agents, drug combinations and synergistic 
natural product combinations were added and significantly expanded in order to 
facilitate target-oriented drug discovery. Currently, 20,818 multi-target agents 
against 385 targets pairs and 115 drug combinations are collected in the TTD, in 
comparison to 3,681 multi-target agents in 2012 update and zero drug combinations 
in 2010 update. The incorporation of these multi-target therapeutics currently in 
development or sold in the market would make TTD more useful for researchers 
studying complex heterogenic diseases.   
 
Target validation data such as the experimentally measured potency of 11,810 drugs 
against 915 targets, the observed potency or effects of 1,436 drugs against 274 
cell-lines and 497 drugs against disease models ( ex vivo, in vivo models), and the 
observed effects of target knockout, knockdown or genetic variations for 307 targets 
were included in TTD. 
 
The major improvement of latest TTD update was the incorporation of the 
information of 1,755 biomarkers for 365 disease conditions to better serve the 
multiple bench-to-clinic communities and to facilitate the development and practice 
of stratified and personalized medicines.  And this feature will be further 
elaborated in detail in the following sections.  
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 The statistics of our updated data is summarized in Table 2.1. 
 
Table 2. 1 Statistics of the drug targets, drugs and their structure and potency data in 2014 







Statistics of Drug Targets 
Number of All Targets 2,360 2,025  
Number of Successful Targets 388 364  
Number of Clinical Trial Targets 461 286  
Number of Research Targets 1,467 1,331  
Statistics of Drugs 
Number of All Drugs 20,667 17,816  
Number of Approved Drugs  






Number of Clinical Trial Drugs 






Number of Discontinued Drugs 498 345  
Number of Pre-Clinical Drugs 163 165  
Number of Experimental Drugs 14,856 14,853  
Number of Multi-Target Agents 20818 3,681  
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Number of Drug Combinations 115 115  
Statistics of Drugs with 
Available Structure or 
Sequence Data 
Number of Small Molecular Drugs 




Number of Antisense Drugs with 




Statistics of Drugs with 
Activity Data or 
Structure-Activity 
Relationship 





Number of Agents with Potency Data 
Against a Disease Model Such As a 




Number of Quantitative 
Structure-Activity Relationship QSAR 
models 
(No of Chemical Types) 
 




2.2 Materials and methods. 
2.2.1 Data collection method 
The relevant information of interest is scattered in the vast collection of medical and 
biological literature such as research articles, reputable review journals, conference 
proceedings and specialized books. Depending on the source of literature and article 
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types, the methods to extract information and to collect data vary. Because of the 
huge amount of literature to search from, an automated literature information 
extraction workflow is desirable and needs to be developed. But it is generally 
difficult to use automatic text mining methods to recognize terms from different 
sources due to the abbreviations, synonyms and different expressions. To ensure the 
reliability of collected data, manual search and curations are necessary. Hence, in 
the development of TTD, the automatic text mining techniques as well as manual 
searching were both used and complemented each other.  
 
In house perl scripts were developed to automatically screen and extract literature 
containing relevant keywords or specific word patterns. The matched literature was 
then examined manually to search for desired information. The automatic text search 
was generally done on abstracts of research articles or conference proceedings first. 
Sometimes meaningful information could already be identified from the abstracts, 
but in many other cases, full articles must be downloaded and read through carefully 
for reliable data and details. 
 
In addition to literature, many established online databases provided valuable 
information and served as curation tools. Chemical databases such as Pubchem, 
MDDR, Chembl, bindingDB, drugbank and Zinc, biological databases such as 
swissprot, uniprot, PDB and KEGG are useful sources of information. In general, 
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SQL query languages were used to automatically extract various kinds of 
information from databases and perl scripts were written to further process and 
format the extracted data. A significant portion of information from different 
databases were shared, but in different formats or presented differently. Efforts were 
done to integrate data from various sources. Through comparison of similar data 
from different sources, the quality of the shared data could be guaranteed. When 
conflicts arise, manual examination is done to further ensure the quantity of data by 
searching for original literature. 
 
2.2.2. Data sources 
Following the general information mining method presented above, the sources of 
various information in TTD will be described in detail.   
 
Newly approved drugs and therapeutic targets were collected from FDA 
Drugs@FDA database (http://www.accessdata.fda.gov/scripts/cder/drugsatfda/) and 
comprehensive search of literatures. Information of drugs and targets in clinical trial 
development was obtained from the latest reports of pharmaceutical companies 
namely Astrazeneca, Bayer, Boehringer Ingelheim, Genentech, GSK, Indenix, 
Incyte, ISIS, Merck, Novartis, Pfizer, Roche, Sanofi Avetis, Schering-Plough, 
Spectrum, Takeda and Teva. The literature search was done by searching the 
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Pubmed using keywords “drug” and “target”, “therapeutic” and “target”, ”clinical 
trial” and “drug”, “clinical trial” and “target”. In addition, some of the newly added 
clinical trial drug information came come from abstract of American Society of 
Clinical Oncology annual meeting. From 1995 to 2011, 2665 abstracts were 
evaluated manually to extract information regarding the clinical trial drugs, such as 
phase, number of participants, result, endpoint, year of study and study design. The 
updated information from clinicaltrial.gov database were also incorporated in the 
database. 
 
Experimentally determined cell-based inhibitory activities of anticancer and 
antibacterial natural products were searched from the Pubmed database (94) by 
using keyword combinations of „natural product‟, „herb‟, „medicinal plant‟, „extract‟, 
„ingredient‟, „GI50‟, „IC50‟, „MIC‟, “activity”, „cell-line‟, and 'in vitro". Till now, 
cell-based inhibitory activities of 1378 anticancer and antimicrobial natural products 
and 99 antimicrobial natural product extracts were obtained from the literatures. For 
natural product with multiple potency data, the best potency was selected and stored.  
 
Literature-reported synergistic natural product combinations were searched from the 
Pubmed database by using keyword combinations „natural product‟, „herb‟, 
„medicinal plant‟, „extract‟, „ingredient‟, „synergistic‟, „synergy‟, „synergism‟, 
„synergize‟, and „potentiate‟. The full reports of the searched articles were evaluated 
Chapter 2 Update of therapeutic target database as an integrated source of targeted therapeutics data 
33 
 
to select those synergistic natural product combinations with the experimental 
cell-based activities available for all constituent natural products both as individual 
and in the respective combination.  
 
For multi-target agents, Pubmed database was searched upon using such keywords 
as „multi-target‟, „dual target‟ and „dual inhibitor‟. Multi-target agent against a target 
pair was defined to be a compound active against both targets at potency values of 
≤20 µM regardless of their possible activities against other targets. The 3D structures 
of these multi-target agents were generated by using CORINA (39) from the 2D 
structures manually drawn based on the literature provided structures or the 
structures found in such chemical databases as BindingDB (40), ChEMBL (41) and 
PubChem (28).  
 
To broadly cover various types of biomarkers, comprehensive literature search was 
conducted in Pubmed database by using combination of keywords “biomarker”, 
“clinical”, “patient”, “disease”, “drug”, and specific disease names. Over 100 review 
papers from reputable journals were downloaded and read through in detail. 
 
Additional sources such as the abstracts of the American society of clinical oncology 
were also systematically searched. From 1995 to 2013, over 700 biomarker related 
abstracts were processed through data mining and curated manually. As far as 
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possible, original research papers cited in the review were checked to collect detailed 
information about the biomarker. And the details collected include the name of 
biomarker, type of biomarker, source of biomarker, measurement, detection method, 
detection threshold, specific disease, specific function of the biomarker, study design, 
number of participants in the study and result.  
2.3. Data in TTD and ways to access them 
2.3.1 Overall search and download options 
Starting from the home page of TTD (Figure 2.1), the users can easily search the 
whole TTD database. Five search fields of disease, drug, drug target, biomarker and 
drug scaffold are listed to help users with different search needs. Customized 
keyword search is also possible in TTD, by accessing the customized search tab 
(Figure 2.2). Target name, drug name, disease indication, target biochemical class, 
drug mode of action and therapeutic class are the specific customized search fields 
for drug and target search. The customized search of biomarkers by their 
development status can be achieved by clicking on “Search biomarker” (Figure 2.3). 
Other than these search methods, target similarity search and drug similarity search 
to search for similar target and drugs given a target FASTA sequence or drug 
structure can be done as well. 
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If the users are not satisfied with the online search and would like to have access to 
more information, full TTD data download is also provided to facilitate batch 
processing of the various data types in TTD (Figure 2.4). Full target information, ID 
mapping of TTD data to public databases, synonyms of chemicals in TTD, drugs, 
target and biomarker mapping to diseases can be easily downloaded and analyzed. 
Specific target information such as sequence and uniprot ID and drug structures in 
SDF format are prepared for download to enable easy analysis and further 
processing of TTD data.  
By inputting keywords in different fields, the users will get access to search pages 
containing all relevant information. And hyperlinks to target, drug and biomarker 
detail information pages are listed.  
  




Figure 2. 1 Screenshot of TTD home page. 




Figure 2. 2 Screenshot of TTD customized search 




Figure 2. 3 Screenshot of TTD customized search of biomarkers 




Figure 2. 4 Screenshot of database download page in TTD. 
 
Chapter 2 Update of therapeutic target database as an integrated source of targeted therapeutics data 
40 
 
2.3.2 Targets and drugs 
The detailed information page for each target includes target name, development 
status of target (successful, clinical trial and experimental), synonyms, disease, 
drugs directed at this target, biochemical class, EC number, pathways, Uniprot ID, 
PDB structure ID, sequence, target validation link, inhibitors of this target included 
in TTD, Multitarget drugs, cross links to 3D structure, related literature and online 
medical dictionary and literature references, if available. Screenshots using ABL1 
protein target as an example can be referred to in Figure 2.5. Many of the fields 
contain hyperlinks to external databases such as swissprot, PDB, KEGG and 
pubmed databases for convenient retrieval of further information. 
 












Figure 2. 5 Screenshots of detailed information page of ABL1 target. 
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The detailed drug information page contains drug name, synonyms, trade name, 
company, indications for use, 2D structure displayed, 3D structure in MOL format 
for download, InChI, InChIKey, canonical SMILES, therapeutic class, CAS number, 
Formula, Pubchem compound ID, Pubchem substance ID, ChEBI id, SuperDrug 
Anatomical Therapeutic Chemical (ATC) ID, SuperDrug CAS ID, therapeutic 
targets and references. Screenshots of drug information page taking Imatinib as an 
example are displayed in Figure 2.6. Cross-links to external chemical databases 
such as Pubchem, DrugBank, SuperDrug and ChEBI can be assessed through the 
IDs listed above and further information could be obtained.   








Figure 2. 6 Screenshots of detailed information page of drug Imatinib. 
 
2.3.3 Biomarkers 
In the main page of TTD database described above, other than the search by target 
and drug options, the most important search field is biomarker. And the 
incorporation of biomarker information is one of the most recent and essential 
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updates to TTD, in view of the current trends towards personalized drug treatment. 
The details of biomarker information in TTD will be highlighted and explained in 
detail here.  
 
Overall 1,755 biomarkers for 365 disease conditions were collected, which included 
both process biomarkers (genetic mutations or alterations, gene amplification, and 
levels of proteins, gene expression, microRNAs, small molecules, or metabolites 
that capture a molecular/biochemical aspect of disease pathogenesis and the 
biological responses to the disease process and/or treatment) and global biomarkers 
(such as tumor sizes, brain structures in neurodegeneration, and shape of cells in 
anemia). These biomarkers may be searched in the “Search for biomarkers” field by 
using keywords or by selecting an ICD-9-CM/ICD-10-CM code (Figure 2.1, Figure 
2.3). 
 
Based on the literature descriptions, our collected biomarkers were classified into 
one or more of the following 11 classes: associative (disease correlation), antecedent 
(pre-illness risk identification), detective (disease early stage detection), 
classification (disease categorization and patient assignment for differential 
treatment), differentiative (differentiation of related diseases), diagnostic 
(recognition of overt diseases), monitoring (monitoring of disease state or treatment 
response), pharmacodynamic (examination of the biological basis of drug response 
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variations), prognostic (prediction of future disease course and response to therapy), 
surrogate (substitute of a clinical end point for predicting therapeutic benefit), and 
theragnostic (identification and monitoring of biochemical effects or mode of action 
of drug and downstream processes) classes. 
 
The biomarker detail information page contains the following fields whenever 
available, biomarker name, target ID (if this biomarker is a protein target in TTD), 
disease, ICD9 and ICD10 disease classification code, biomarker type (i.e. diagnostic, 
prognostic, etc) , molecule type (i.e. gene mutation, protein expression, microRNAs, 
small molecules, etc) , development phase ( in clinical use or clinical trial), method 
to detect this biomarker (i.e. polymerase chain reaction (PCR), enzyme-linked 
immunosorbent assay (ELISA), mass spectrometry (MS), western blot, imaging, etc), 
measure (i.e. loss of function in a particular gene, elevated or reduced expression 
level of a biomarker, etc), specific use of the biomarker ( i.e. to predict response to 
treatment, to predict survival rate, to monitor disease progression, to indicate 
adverse treatment effects, etc), conclusion of the biomarker study from literature, 
specific conclusion( usually give more details of the results of a biomarker study), 
treatment (if the biomarker is related to certain treatment or to predict the response 
to treatment), reference, uniprot ID and hyperlinks to gene bank, Chembl, Pfam, 
PDB, gene expression atlas, KEGG and gene ontology external databases. 
Screenshot of the biomarker information page can be seen in Figure 2.6 using p53 
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in colon cancer as an example. A biomarker can have multiple functions in different 
disease conditions and, for each function, a table similar to the screenshot in Figure 
2.7 will be displayed if that biomarker is searched for. 
 




Figure 2. 7 Screenshot of biomarker detail information of p53. 
   
Chapter 2 Update of therapeutic target database as an integrated source of targeted therapeutics data 
51 
 
2.3.4 Multi-target agents and drug combinations 
The multi-target agents can be retrieved by clicking the „Multi-Target Agents‟ field 
in the TTD home page, which leads to the TTD multi-target agents page where a 
user can download the multi-target agents against a specific target pair from the 
target pair list (Figure 2.8). For each target, if drugs against that particular target can 
also bind to other targets, then the multitarget agents are listed in the page and linked 
to the specific drug pages.  
 
Similarly, the drug combinations can be retrieved by clicking on the “drug 
combination” tab. And drug-combination data, which include 72, 14 and 4 
pharmacodynamically synergistic, additive, and antagonist combinations, and 19 and 
7 pharmacokinetically potentiative and reductive combinations together with their 
mode of actions and combination mechanisms, are available for users to download. 
 




Figure 2.8 Screenshot of multi-target agents download page. 
 
2.3.5 International Classification of Disease  
From the TTD webpage (Figure 2.2), users can choose the “Search drugs and 
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targets by disease or ICD identifier ” field to search TTD target and drug entries by 
inputting disease names or selecting ICD-9-CM or ICD-10-CM codes. The TTD 
biomarker entries can be searched by ICD-9-CM or ICD-10-CM codes from the 
“Search for biomarkers” field. Users may also download from the TTD download 
page the lists of TTD target, drug and biomarker entries with the corresponding 
ICD-9-CM and ICD-10-CM codes. 
 
ICD, short for International Classification of Disease, has been developed by WHO, 
sponsored by the United Nations, adopted by > 110 countries, and used by 
physicians, researchers, nurses, health workers, health information managers, 
policy-makers, insurers and health program managers for defining diseases, studying 
disease patterns, managing health care, monitoring outcomes and allocating 
resources (92, 93).  ICD codes have been regularly revised to the current version of 
ICD-10 (92). But the previous version ICD-9 is still used by some organizations 
while proceeding with transition to ICD-10 (the expected completion date for the 
transition to ICD-10 in the United States is October 1
st
 2014) (95). ICD-10 is 
composed of 68,000 alphanumeric codes as compared to the 13,000 numeric codes 
of ICD-9, thus offering more comprehensive coverage and better representation of 
medical conditions (92). A number of nations have developed their own adaptations 
of the ICD codes. For instance, the United States have developed ICD-9 and ICD-10 
clinical modification ICD-9-CM (17,000 codes) and ICD-10-CM (155,000 codes) 
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for covering additional morbidity details (96), which were used in TTD because of 
their more comprehensive coverage. Table 2.2 provides the list of ICD-9-CM and 
ICD-10-CM code blocks together with the corresponding disease classes. 
 
Table 2. 2 List of ICD-9-CM and ICD-10-CM code blocks and the corresponding classes of 










Class of diseases or related health problems 
I  001–139 A00-B99  Certain infectious and parasitic diseases  
II  140–239 C00-D48  Neoplasms  
III  279–289 D50-D89  Diseases of the blood and blood-forming organs and 
certain disorders involving the immune mechanism 
IV  240–278 E00-E90  Endocrine, nutritional and metabolic diseases 
V  290–319 F01-F99  Mental and behavioral disorders  
VI  320–359 G00-G99  Diseases of the nervous system  
VII  360–379 H00-H59  Diseases of the eye and adnexa  
VIII  380–389 H60-H95  Diseases of the ear and mastoid process  
IX  390–459 I00-I99  Diseases of the circulatory system  
X  460–519 J00-J99  Diseases of the respiratory system  
XI  520–579 K00-K93  Diseases of the digestive system  
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XII  680–709 L00-L99  Diseases of the skin and subcutaneous tissue 
XIII  710–739 M00-M99  Diseases of the musculoskeletal system and connective 
tissue 
XIV  580–629 N00-N99  Diseases of the genitourinary system  
XV  630–679 O00-O99  Pregnancy, childbirth and the puerperium  
XVI  760–779 P00-P96  Certain conditions originating in the perinatal period 
XVII  740–759 Q00-Q99  Congenital malformations, deformations and 
chromosomal abnormalities 
XVIII  780–799 R00-R99  Symptoms, signs and abnormal clinical and laboratory 
ﬁndings, not elsewhere classiﬁed 
XIX  800–999 S00-T98  Injury, poisoning and certain other consequences of 
external causes 
XX  E000-E999 V01-Y98  External causes of morbidity and mortality  
XXI  V01-V91 Z00-Z99  Factors inﬂuencing health status and contact with health 
services 
 
The ICD-9-CM and ICD-10-CM codes were matched to the TTD target, drug and 
biomarker entries by the following procedures: First, automated word match was 
conducted for matching the disease name or names of each TTD target, drug or 
biomarker entry with the disease descriptions of each ICD codes. Secondly, each of 
the fully or partially matched TTD entry was manually checked to either validate the 
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match or to find the right ICD codes. Thirdly, manual search was conducted for 
those TTD entries without a single match. So far, ICD codes for 785 targets and 
3,080 drugs that are linked to 732 disease conditions have been found.  
 
The 1755 literature-reported biomarkers were also linked to ICD codes. By linking 
the ICD and biomarker codes, the relevant information may be conveniently 
accessed by clicking an icon beside a disease name/code in an E-health system. 
Most biomarkers are molecular-based, which present an educational challenge for 
those users who are only familiar with the histopathology-based 
disease-classification systems. Linking ICD and biomarker codes enables easy 
cross-links to bioinformatics resources for genomic, structural, pathway and 
functional information.  
 
In addition, the linking of ICD codes to targeted therapeutics information like 
biomarkers makes it possible to analyze the disease coverage pattern of such 
therapeutics. And chapter 5.2 gives an example of such analysis on non-invasive 
molecular biomarkers in detail. 
 
A new ICD version ICD-11 is in development and scheduled for endorsement by 
WHO in 2015 (97), which offers more refined disease classification based on more 
recent scientific understanding of the disease mechanisms. For instance, small cell 
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lung cancer, which represents approximately 13% of all lung cancer diagnoses (98), 
is not explicitly classified in the ICD-10 and earlier ICD versions but is now 
explicitly represented in the ICD-11 beta draft. Therefore, ICD-11 is expected to be 
more useful for developing a more refined disease classification system for stratified 
and personalized medicine. Effort will be made to upgrade TTD to the ICD-11 
version upon its official release. Moreover, suggestions to be made to ICD codes for 
more refined disease classification will be discussed in chapter 5.1.  
 
2.4 Future work 
The efforts in the discovery and application of targeted therapeutics increasingly 
involve collective efforts from multiple bench-to-clinic communities (24-26) and are 
moving more and more towards stratified and personalized medicines (27-29). The 
drug, target, biomarker, and other relevant chemical, biological, pharmaceutical and 
clinical data need to be more integrated and be made easily accessible by the 
multiple bench-to-clinic communities.  
 
The updated TTD database continues to be a primary source providing integrated 
information about targeted therapeutics with easily accessible features by biological 
researchers, pharmaceutical industry and medical practicers. Over 130,000 clicks to 
TTD database since its construction and over 44000 click counts of visit to TTD 
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since its last update demonstrate its popularity and important role in the field of 
pharmaceutical research.   
 
Continuous efforts will be made to expand the linkage of the ICD and ATC codes to 
drugs, efficacy targets and biomarkers and to provide the latest and comprehensive 
information about the drugs, efficacy targets and biomarkers for better serving the 
multiple bench-to-clinic communities in their collective efforts for the discovery, 
investigation, application, monitoring and management of targeted therapeutics. 
 
Potential biomarkers, particularly multi-markers, have also been predicted from the 
genetic and gene expression data of patients by using such computational methods 
as the principal components analysis feature selection method (99), weighted voting 
classification feature selection method (100), hierarchical clustering feature 
selection method (101), differentially expressed genes method (102, 103), and 
machine learning feature selection methods (104, 105). These potential biomarkers 
may also be included in TTD and other biomarker databases for facilitating their 
future exploration. 
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Chapter 3: Methods to learn from known drugs and inhibitors for 
the design of multi-target small molecule drugs 
Information of known drugs and inhibitors is a valuable source to facilitate the 
design of traditional multi-target small molecule drugs. Machine learning methods 
can be implemented as virtual screening tools to learn from physiochemical 
properties of the known inhibitors and make predictions to select virtual hits that act 
on multiple targets simultaneously. The performance of the machine learning 
methods for prediction of multi-target agents was evaluated in Chapter 3.1. Through 
the hierarchical clustering method described in Chapter 3.2, drugs, inhibitors and 
similar compounds can be clustered and possible drug distribution patterns could be 
learnt by analysing the cluster patterns. 
 
3.1 Evaluation of Hit and Target Selection Performance 
of Machine Learning Multi-Target Virtual Screening 
Methods  
In this work, the multi-target hit and target selection performance of 3 
extensively-used machine learning methods, Combi-SVM, combinatorial k-Nearest 
Neighbour (Combi-kNN) and combinatorial Probabilistic Neural Network 
(combi-PNN) in the VS of dual inhibitors of 29 target pairs of high, intermediate and 
low similarity levels between their drug-binding domains was systematically 
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evaluated. These target pairs cover 8 therapeutically explored biochemical classes 
including kinases, proteases, transporters, GPCRs, reductases, synthases, cytokines, 
and DNA-binding proteins. The yield of multi-target hits of the three VS methods 
was rigorously tested by using individual target inhibitors as training datasets (all 
known dual inhibitors are excluded) and the known dual inhibitors as independent 
testing datasets of these VS methods. Such tests are particularly useful for testing the 
capability of these methods in identifying multi-target inhibitors without explicit 
knowledge of multi-target agents (23). Target selectivity of these VS methods were 
assessed by measuring the false hit rates in misclassifying individual-target 
inhibitors of a target pair and inhibitors of the other targets in the same biochemical 
class as dual inhibitors of the target pair. Moreover, the ability of these VS methods 
in searching large compound libraries were evaluated by using them to screen 17 
million and 168,000 compounds from the PubChem and MDL Drug Data Report 




3.1.1.1 Datasets and molecular descriptors 
Based on sequence similarity between their drug binding domains obtained from 
PFAM, the 29 target pairs were classified into 3 classes, namely low, intermediate 
and high similarity classes. According to Rost‟s finding that proteins with >40% 
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sequence identity unambiguously distinguish similar and non-similar structures 
while the distinction signal gets blurred in the twilight zone of 20-30% (106) , the 
target pairs were classified into high, intermediate and low similarity classes with 
their drug-binding domains at sequence identity levels of >40%, 20-40% and <20% 
respectively (Table 3.1). The high-similarity target-pairs include SERT-NET, 
Src-Lck, VEGFR2-Lck, CDK1-CDK2 and PDGFR-FGFR. The 
intermediate-similarity target-pairs include EGFR-Src, CDK2-GSK3, 
MMP2-MMP3, EGFR-FGFR, CDK1-GSK3, EGFR-PDGFR, Aurora-GSK3, 
PDGFR-Src, Aurora-Met, Aurora-HER2 and CDK1-VEGFR2. The low-similarity 
target-pairs include PKC-Topoisomerase, SERT-5HT1b, Aggrecanase-MMP1, 
DHFR-Thymidylate Synthase, Aggrecanase-MMP9, Aggrecanase-TNFα, 
Aggrecanase-MMP2, SERT-5HT1a, HER2-MMP2, HER2-MMP9, and SERT-H3. 
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Table 3. 1 Datasets of individual-target and multi-target inhibitors of the target-pairs used for developing and testing machine learning multi-target inhibitor 
virtual screening tools.  Additional sets of 17 million PubChem compounds and 168,000 MDDR active compounds were also used for the test. 
Target Pair Inhibitors in Training Sets Inhibitors in Testing Sets 
Target A – Target B Drug-binding domain similarity 
level (sequence identity) 
Biochemical class No of inhibitors 
of A that are 
non-inhibitor of 
B  
No of inhibitors of 
B that are 
non-inhibitor of A 
No of multi-target 
agents of A and B 
No of inhibitors of 
other targets in the 
same biochemical 
class 
SERT-NET High-similarity (72.3%) Transporter-Transporter 1125 1410 101  
Src-Lck High-similarity (67.1%) Kinase-Kinase 804 450 56 4906 
VEGFR2-Lck High-similarity (66.9%) Kinase-Kinase 1232 445 61 4515 
CDK1-CDK2 High-similarity (66.8%) Kinase-Kinase 484 650 174 4945 
PDGFR-FGFR High-similarity (40.4%) Kinase-Kinase 450 233 230 5339 













MMP2-MMP3 Intermediate-similarity Protease-Protease 674 662 12 1918 

















































       





SERT-5HT1b Low-similarity (15.1%) Transporter-GPCR 1894 917 57  
Aggrecanase-MMP1 Low-similarity (11.9%) Protease-Protease 252 1289 44 1692 
DHFR-thymidylate 
synthase 




Chapter 3: Methods to learn from known drugs and inhibitors for the design of multi-target small molecule drugs 
64 
 
Aggrecanase-MMP9 Low-similarity (10.1%) Protease-Protease 279 340 17 2668 
Aggrecanase-TNFalpha Low-similarity (9.0%) Protease-Cytokine 281 68 15 3008 
Aggrecanase-MMP2 Low-similarity (10.7%) Protease-Protease 286 676 10 2344 
SERT-5HT1a Low-similarity (8.0%) Transporter-GPCR 1679 1144 216  
HER2-MMP2 Low-similarity (4.8%) Kinase-Protease 936 659 27 6564 
HER2-MMP9 Low-similarity (2.4%) Kinase-Protease 951 345 12 6895 
SERT-H3 Low-similarity (1.7%) Transporter-GPCR 1804 1689 147  




Individual-target and dual-target inhibitors for the 29 target pairs (Table 3.1), each 
with IC50≤20 µM, were collected from the literatures and public databases such as 
ChEMBL (107) and BindingDB (108) databases. As few non-inhibitors have been 
reported, putative non-inhibitors of each target were generated by using our method 
reported in our earlier publications (109, 110). In our method, 13.56 million 
PubChem and 168 thousand MDDR compounds were clustered into 8,993 
compound families(111). The number of our derived compound families are 
consistent with the reported 12,800 groups of topologically close structures for 26.4 
million compounds of up to 11 atoms (112), and 2,851 clusters for 171,045 natural 
products (113). 5 representative compounds were selected from each family that 
contain no known individual-target and dual-target inhibitors as the putative 
non-inhibitors for developing the three VS tools. This approach has the risk of 
wrong inclusion of the compound families that contain undiscovered multi-target 
and individual-target inhibitors into the non-inhibitor training dataset.  The 
maximum possible “wrong” classification rate arising from these mistakes has been 
estimated at <13% even in the extreme and unlikely cases that all of the 
undiscovered single-target and multi-target agents as well as the known multi-target 
agents are misplaced into the non-inhibitor class (110, 114, 115). The noise level 
generated by up to 13% “wrong” negative compound family representation is 
expected to be substantially smaller than the noise level tolerated by machine 
learning methods such as SVM (116). 




Each compound (including putative non-inhibitors) was represented by 98 1D and 
2D molecular descriptors derived from our own software (117), which are composed 
of 18 descriptors in the class of simple molecular properties, 3 descriptors in the 
class of chemical properties, 35 descriptors in the class of molecular connectivity 
and shape, 42 descriptors in the class of electro-topological state. These descriptors 
have been extensively used in deriving structure-activity relationships (118), 
quantitative structure activity relationships (119) and machine learning VS methods 
for individual-target (110, 114, 115) and multi-target (23) agents.  
 
3.1.1.2 Support vector machines 
Based on the structural risk minimization principle of statistical learning theory 
(120), SVM performs well consistently with good classification capability, fast 
classification speed, low over-fitting risk, relative insensitivity to sample redundancy 
and ability to work on structurally diverse large datasets (121, 122). Though the 
performance of SVM is limited by the insufficient knowledge of known inhibitors 
for many targets, it is a useful tool to complement other virtual screening tools with 
comparable performances or improvement in aspects like reduced false-hit rates.   
 
A linear SVM model tries to construct a hyper-plane that perfectly separates the 
active and inactive classes of compounds, represented by vectors of their molecular 
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descriptors in the multidimensional feature space, and maximizes the margin, 
defined as the closest distance from any vector point to the hyper-plane. 
Mathematically, the hyper-plane satisfies the following conditions: 
 
1,  for 1i ib y     w x  
Active class   
    1,  for 1i ib y     w x  Inactive class 
where yi is the class index, w is a vector normal to the hyper-plane, /b w  is the 
perpendicular distance from the hyper-plane to the origin and 
2
w  is the Euclidean 
norm of w. Base on w and b, a given vector x can be classified by f(x) =
[( ) ]sign b w x .  A positive or negative f(x) value indicates that the vector x 
belongs to the active or inactive class respectively 
 
For the classification of compounds with diverse structures, a nonlinear SVM is 
frequently used, as the input vectors are not linearly separable. Kernel functions are 
used to map input vectors into a higher dimensional feature space that can be 
linearly separated. We used the radial basis function kernel  
 , which are commonly used and proven to have 
consistent better performance over other kernel function (110, 114, 115). Linear 
SVM was then applied to this feature space based on the following decision function
0
1




f sign y K b

 x x x , where the coefficients i0 and b were determined 
by maximizing the following Langrangian expression: 








i i j i j i j
i i j
y y K 
  








0 . A positive or negative f(x) value indicates that the vector x belongs to 
the active or inactive class respectively.  Our SVM VS models were developed by 
using a hard margin c=100,000 and their σ values are in the range of 0.1-2. In terms 
of the numbers of true positives TP (true inhibitors), true negatives TN (true 
non-inhibitors), false positives FP (false inhibitors), and false negatives FN (false 
non-inhibitors), the yield and false-hit rate are calculated by TP/ (TP+FN) and FP/ 
(TP+FP) respectively.    
 
3.1.1.3 k-Nearest Neighbour  
k-nearest neighbour (k-NN) is a classification method based on the nearest input 
training vectors in the multidimensional feature space. It measures the distance of a 
to-be-classified vector x and each individual vector xi in the training set, and the 
unknown vector is assigned to the class which majority of its k nearest neighbours 
belong to. (123, 124) The most common distance metric used is Euclidean distance, 
calculated using the formula: 
2
iD  x x . k vectors nearest to the vector x are 
used to determine its class  1








( , ) 1 if  and ( , ) 0 if a b a b a b a b      , argmax is the maximum of the function, 
V is a finite set of vectors {v1,…vs} and 
ˆ ( )f x  is an estimate of f(x) and is 
assigned to the same class as the most frequent class of the k nearest neighbours. 
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The best parameter k of constructed k-NN models is chosen to be in the range of 
k=1 or 3 or 5 or 9, based on the highest yield of dual inhibitor prediction.  
 
3.1.1.4 Probabilistic Neural Network 
Probabilistic Neural Network (PNN) is a classification method based on Bayes‟ 
optimal decision rule (125): ( ) ( )i i i j j jhc f h c fx x , where hi and hj are the prior 
probabilities, ci and cj are the costs of misclassification and fi(x) and fj(x) are the 
probability density function for class i and j respectively. 
 
An unknown vector x is classified into population i if the product of all the three 
terms is greater for class i than for any other class j (not equal to i). In most 
applications, the prior probabilities and costs of misclassifications are treated as 
being equal. The probability density function for each class for a univariate case can 
be estimated by using the Parzen‟s nonparametric estimator, 
           
1
1









x                 
where n is the sample size,  is a scaling parameter which defines the width of the 
bell curve that surrounds each sample point, W(d) is a weight function which has its 
largest value at d = 0 and (x – xi) is the distance between the unknown vector and a 
vector in the training set. The Parzen‟s nonparametric estimator was later expanded 
by Cacoullos for the multivariate case. 
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n   

    
The Gaussian function is frequently used as the weight function because it is well 
behaved, easily calculated and satisfies the conditions required by Parzen‟s estimator. 
Thus the probability density function for the multivariate case becomes 












    
 
 x                  
 The network architectures of PNN are determined by the number of compounds 
and descriptors in the training set. There are 4 layers in a PNN. The input layer 
provides input values to all neurons in the pattern layer and has as many neurons as 
the number of descriptors in the training set. The number of pattern neurons is 
determined by the total number of compounds in the training set. Each pattern 
neuron computes a distance measure between the input and the training case 
represented by that neuron and then subjects the distance measure to the Parzen‟s 
nonparameteric estimator. The summation layer has a neuron for each class and the 
neurons sum all the pattern neurons‟ output corresponding to members of that 
summation neuron‟s class to obtain the estimated probability density function for 
that class. The single neuron in the output layer then estimates the class of the 
unknown vector x by comparing all the probability density function from the 
summation neurons and choosing the class with the highest probability density 
function. The parameters of the developed PNN models for the evaluated targets are 
in the range of δ=0.001~0.015. And the optimal parameter is chosen based on the 
highest yield of dual inhibitor prediction.  Only two classes (active or inactive) are 
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trained in the PNN models to predict inhibitors.  
3.1.2 Results and discussion 
3.1.2.1 Dual inhibitor yields  
The VS performances of the three VS methods for high, intermediate and low 
similarity target pairs are shown in Table 3.2 respectively and in Figure 3.1. All 
three VS methods showed comparable dual-inhibitor yields for the target pairs at all 
similarity levels. Specifically, the dual inhibitor yields of Combi-SVM, Combi-kNN 
and Combi-PNN are in the range of 17.65%-77.80%, 10.90%-88.89%, and 38.1-100% 
in searching low similarity target pairs, 14.63%-73.10%, 5.56%-66.7%, and 
14.63%-75.00% in searching intermediate similarity target pairs, and 
38.26%-75.00%, 16.09%-67.86%, and 21.30%-83.93%  in searching high 
similarity target pairs respectively. These yields are comparable to the yields of dual 
kinase inhibitors and dual-target serotonin reuptake inhibitors produced by 
Combi-SVM in our earlier studies (23). These yields are also comparable to that of 
QSAR method reported in the literature. A recently developed multi-target kinase 
inhibitor QSAR model correctly identified the dual targets of 2 (66.6%) of the 3 dual 
kinase inhibitors (EGFR-Lck inhibitor Pelitinib, and VEGFR2-PDGFR inhibitors 
Sunitinib and Sorafenib) tested among several kinase inhibitors (47). 
Table 3. 2 Virtual screening performance of combinatorial SVMs for identifying dual-target 
inhibitors of high similarity target pairs  
Target Pair Method Virtual Screening Performance 
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 Target A – Target B  Multi-targe
t inhibitors 
Inhibitors of 
individual target of 
the target-pair 
inactive against the 






































49.5% 22.4% 29.8% 2.4% 0.12%  0.035%  
 kNN 59.40% 19.80% 25.10%  0.580%  




75.00% 16.42% 7.61% 0.84% 0.034% 0.011% 
 kNN 67.86% 14.55% 22.02%  0.140%  




52.46% 29.21% 6.49% 3.39% 0.104% 0.036% 
 kNN 42.62% 9.90% 30.79%  0.208%  




52.3% 39.2% 48.1% 3.4% 0.075% 0.022% 
 kNN 16.09% 21.83% 18.71%  0.170%  




38.26% 13.78% 22.75% 4.44% 0.056% 0.013% 
 kNN 36.96% 13.11% 30.47%  0.139%  
 PNN 60.87% 28.00% 48.50%  0.665%  




26.8% 12.9% 11.1% 1.49% 0.096% 0.033% 
 kNN 51.79% 12.38% 25.63%  0.243%  




34.67% 8.00% 9.35% 0.77% 0.071% 0.016% 
 kNN 30.67% 15.58% 15.65%  0.164%  
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66.67% 27.45% 23.41%  0.13% 0.018% 
 kNN 66.67% 36.65% 35.95%  0.714%  




40.85% 7.37% 8.16% 1.38% 0.071% 0.015% 
 kNN 52.50% 12.36% 22.45%  0.169%  




30.32% 8.00% 9.35% 1.15% 0.037% 0.018% 
 kNN 25.81% 12.40% 10.59%  0.082%  




27.60% 9.20% 14.30% 1.88% 0.100% 0.031% 
 kNN 34.50% 14.74% 27.17%  0.274%  




47.73% 13.24% 4.87% 0.13% 0.118% 0.053% 
 kNN 36.36% 9.38% 9.40%  0.152%  




38.3% 25.8% 11.6% 1.81% 0.10% 0.021% 
 kNN 40.40% 34.96% 19.23%  0.242%  




16.7% 3.6% 9.3% 0.8% 0.018% 0.0095% 
 kNN 5.56% 6.45% 6.79%  0.052%  




73.1% 20.4% 13.7% 1.1% 0.1% 0.034% 
 kNN 34.62% 19.86% 15.90%  0.167%  
 PNN 61.54% 33.19% 28.18%  0.550%  
CDK1-VEGFR2 Combi-SV
M 
14.63% 0.78% 1.73% 4.77% 
  
 kNN 14.63% 15.09% 10.76%  0.200%  
 PNN 14.63% 1.24% 0.68%  0.840%  
       
PKC-Topoisomerase Combi-SV
M 
77.8% 3.2% 0.35%  0.022% 0.0065% 
 kNN 88.89% 3.98% 5.96%  0.085%  
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 PNN 66.67% 3.72% 6.34%  0.109%  
SERT-5HT1b Combi-SV
M 
38.6% 13.8% 37.9% 3.4% 0.24% 0.035% 
 kNN 31.60% 14.10% 32.60%  0.750%  
 PNN 45.60% 4.70% 30.30%  2.830%  
Aggrecanase-MMP1 Combi-SV
M 
50.00% 16.67% 5.35% 3.31% 0.065% 0.008% 
 kNN 31.82% 23.41% 5.35%  0.139%  





39.6% 27.5% 33.4%  0.14% 0.02% 
 kNN 33.81% 21.37% 24.42%  0.179%  
 PNN 46.76% 32.70% 33.75%  0.323%  
Aggrecanase-MMP9 Combi-SV
M 
17.65% 5.38% 4.41% 2.25% 0.030% 0.004% 
 kNN 11.76% 6.45% 6.76%  0.062%  





46.67% 2.14% 1.47% 0.70% 0.012% 0.000% 
 kNN 33.33% 2.14% 5.88%  0.023%  
 PNN 100.00% 4.98% 4.41%  0.011%  
Aggrecanase-MMP2 Combi-SV
M 
60.00% 7.34% 10.50% 1.83% 0.027% 0.004% 
 kNN 50.00% 7.69% 9.47%  0.077%  
 PNN 80.00% 25.87% 14.50%  0.377%  
SERT-5HT1a Combi-SV
M 
47.7% 15.4% 19.4% 7.1% 0.28%  0.054%  
 kNN 34.30% 16.60% 24.30%  0.830%  
 PNN 45.40% 38.90% 34.30%  3.400%  
HER2-MMP2 Combi-SV
M 
74.07% 2.03% 1.97% 0.49% 0.010% 0.006% 
 kNN 29.63% 1.60% 2.28%  0.032%  
 PNN 77.78% 4.81% 3.79%  0.175%  
HER2-MMP9 Combi-SV
M 
41.67% 2.31% 2.03% 0.45% 0.001% 0.001% 
 kNN 50.00% 1.05% 2.61%  0.007%  
 PNN 75.00% 3.05% 2.61%  0.035%  
SERT-H3 Combi-SV
M 
25.9% 5.4% 8.2% 3.5% 0.067% 0.028% 
 kNN 10.90% 9.00% 8.50%  0.410%  
 PNN 38.10% 25.50% 22.20%  2.350%  





Figure 3. 1 Dual model performance of three machine learning methods. 
 
As shown in Figure 3.1, the dual inhibitor yields tend to show larger variations at 
decreasing similarity between the drug-binding domains of the target pairs. This 
suggests that it is more difficult to produce consistent dual inhibitor yields for lower 
similarity target pairs. Cases of disagreement between sequence-based similarity and 
binding site similarity have been reported (126). In particular, some protein pairs 
with very low similarity at the sequence level may have high levels of similarity in 
their binding site surface characteristics (127). On the other hand, it has been found 
that some multi-target agents bind to targets of different families with different 
binding site structures by adopting substantially different conformations (induced fit) 
and relying on additional help such as metal binding (128-130). These factors may 
not be fully captured by currently available molecular descriptors and machine 
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higher binding site similarity are expected to be more easily identified by machine 
learning methods than those of the target pairs with lower binding site similarity, 
which may partly contribute to the larger variations of dual inhibitor yields for low 
similarity pairs.  
 
3.1.2.2 Target selectivity  
Target selectivity against individual target inhibitors of the same target pair was 
tested by using the three machine learning methods to screen the 68-1894 individual 
target inhibitors of each target-pair to determine the percentage of individual target 
inhibitors of the same target pair incorrectly predicted as dual inhibitor of the target 
pair.  As shown in Table 3.2, Combi-SVM, Combi-kNN and Combi-PNN 
misidentified 0.35%-37.90%, 1.05%-32.60%, and 2.61-43.25% of the 
individual-target inhibitors as dual-inhibitors for low similarity pairs, 0.78%-25.80%, 
6.45%-36.65%, and 0.68-49.55% for intermediate similarity pairs, and 
6.49%-48.10%, 9.90%-30.79%, and 20.70-52.30% for high similarity pairs, 
respectively. Therefore, all three methods are reasonably selective in distinguishing 
dual inhibitors from individual-target inhibitors of the same target pairs. As shown in 
Figure 3.2, the selectivity of all three methods against individual-target inhibitors 
tends to be significantly decreased when similarity level of the target pairs is 
increased. This is consistent with the findings from several reported target selectivity 
studies. It has been reported that inhibitors tend to become less selective to binding 
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sites with less distinct physicochemical properties (131). The structure-activity 
landscapes of the bioactive compounds of closely related targets are expected to 
include overlapping and distinct regions of multi-target agents many of which with 
structures similar to the individual-target inhibitors (132). These factors may make it 
harder for machine learning methods to distinguish dual-target and individual-target 
inhibitors for high similarity target pairs. Two additional factors may contribute to 
the misclassification of individual target inhibitors as dual inhibitors. First, the three 
methods were trained by using individual target inhibitors only, which are not 
expected to fully distinguish dual inhibitors from individual-target inhibitors. 
Secondly, some of the misidentified individual target inhibitors may be true dual 



































Figure 3. 2 Selectivity of three methods against individual-target inhibitors 
 
Target selectivity was further tested by using SVM method to screen the inhibitors 
of the other targets in the same biochemical class studied in this project outside the 
target pair (Table 3.2) We found that small percentages of 0.45%-7.10% of the 
individual-target inhibitors were misidentified by Combi-SVM as dual-inhibitors for 
low similarity pairs, 0.13%-4.77% for intermediate similarity pairs, and 0.84%-4.44% 
for high similarity pairs respectively. Compared to their selectivity against 
individual target inhibitors, Combi-SVM is significantly more selective against 
inhibitors of other targets in the same biochemical class outside the target-pair, and 
the selectivity is insensitive to the level of similarity of the target pairs. This is 
consistent with the conclusions from extensive studies of kinase selectivity profiles 
of kinase inhibitors. Screening of two scaffold groups of 118 compounds against a 
panel of 353 kinases has shown that each scaffold has distinct kinase selectivity 
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Global kinase target profiling of several BCR-ABL kinase inhibitors imatinib, 
nilotinib, dasatinib, bosutinib, and INNO-406 has shown that each of these inhibitors 
exhibits overlapping but distinct inhibition profiles across the whole kinase panel 
(134-136). Although kinase inhibitors have a propensity to cross-interact with 
multiple kinases, not all kinases are equally likely to interact with small molecules 
(137). An earlier analysis of corporate data suggests that kinase frequent hitters are 
far fewer in numbers than kinase selective inhibitors (138). These studies have 
consistently shown that kinase inhibitors have no apparent propensity to 
cross-interact with other kinases of similar drug-binding domain sequences. One 
may further speculate that inhibitors of other biochemical classes behave in a similar 
way. 
 
3.1.2.3 Virtual screening performance in searching MDDR database  
As shown in Table 3.2, the numbers of dual inhibitor virtual-hits identified by 
Combi-SVM, Combi-kNN and Combi-PNN and the corresponding virtual-hit rates 
in screening 168,000 MDDR compounds are 0.00%-0.28%, 0.01%-0.83% and 
0.01%-3.40% for low similarity pairs, 0.02%-0.12%, 0.05%-0.71%, and 0.12%-0.97% 
for intermediate similarity pairs, and 0.03%-0.12%, 0.14%-0.58%, and 0.47%-3.14% 
for high similarity pairs respectively. As shown in Figure 3.3, the virtual hit rates of 
the 3 methods are relatively insensitive to the similarity levels of the target pairs. 
One possible reason for the low sensitivity to target pair similarity is that most of the 
MDDR compounds are significantly different in structural and physicochemical 
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properties to the dual inhibitors and individual target inhibitors of the evaluated 
target pairs.  
 
 
Figure 3. 3 The virtual hit rates of three machine learning methods to screen MDDR 
Given the possibility that some of the identified MDDR virtual hits may be true dual 
inhibitors, the true false hits rates of the 3 methods are likely smaller than the 
computed virtual hit rates. Therefore, the false hit rates of Combi-SVM, 
Combi-kNN and Combi-PNN can be estimated as ≤0.00%-0.28%, ≤0.01%-0.83% 
and ≤0.01%-3.4% in screening MDDR compounds respectively. These rates are 
comparable and in some cases better than the false-hit rates of 0.02%-0.37% and 
0.05%-0.35% produced by some of the machine learning methods and molecular 
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3.1.3 Future work  
As discussed in previous section, the virtual screening performance of machine 
learning approaches needs further improvement. Among the many aspects that could 
be improved, a lower false hit rate is desired when screening large databases like 
Pubchem. This is to ensure that a sufficient percentage of virtual hits are true hits so 
as to reduce the costs of wet lab validations.  
 
To decrease the false hit rate, a better method to generate putative non-inhibitor is 
necessary. The Pubchem database has been updated, so by keeping our 
SVM-formatted Pubchem screening library up to date, the putative non-inhibitors 
generated could be more representative of the whole chemical space.  
 
In the above method section, 13.56 million Pubchem compounds were clustered to 
over 8000 families in order to generate the putative negatives. Due to the significant 
increase in the size of Pubchem compound structures, efforts have been made to 
recluster the updated Pubchem. 29.7 million Pubchem compounds with distinct 
structures were cleaned, formatted and clustered. The more than two fold increase in 
the number of Pubchem compounds was beyond the computational power of our 
current computers using k-means clustering. After running consecutively for 2 
months, the k-means clustering method still did not generate any clustering results. 
Hence, in house script was written in Fortran to split the Pubchem chemical space 
into parts and then k-means was applied to each part to divide the part of chemical 
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space into smaller clusters of compounds families. The idea of this Fortran script 
was to find the center of the chemical space first and then calculate the Euclidian 
distance between each data points to the center. Groups of points within a certain 
range of distance to the center points, which can be visualized as a spherical ring if 
in 3D space, will be classified as one part of chemical space. The 29.7 million 
Pubchem compound space was split into 168 such parts. And then each part was 
clustered using kmeans method into families and the parameter K used was around 
300 on average for each part, depending on the number of data points in each part. 
In the end, a total of around 60000 chemical families were identified from the 
Pubchem compound library. And the performance of this newly clustered chemical 
families is still under evaluation. Preliminary results indicate that SVM using 
putative negatives generated by these new chemical families could scan the 29.7 
million Pubchem compound library with a lower hit rate. But the performance of 
SVM in terms of specificity and sensitivity still needs to be fine-tuned.         
 
In addition, SVM can be modified to accommodate the need for lower false hit rate 
through iteratively throwing away the non-support vector negatives and adding in 
new putative negatives. Through this method, SVM models are expected to better 
differentiate those compounds situated at the border of SVM hyperplane.     
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3.2 Hints of drug prolific regions and properties by 
clustering drugs in the target-specific chemical space   
The above VS tools developed have a reasonably good yield to identify virtual hits 
from the large chemical libraries. But as reviewed in the introduction, from hit to 
lead and from lead to drugs, the drug discovery process is still lengthy and costly, 
especially with the high attrition rates in clinical trials. More methods were needed 
to shorten the process and to increase the success rate. A hierarchical clustering 
method was proposed to cluster known drugs in the target-specific chemical space. 
This chemical space is spanned by the compounds from large chemical libraries 
whose structures are similar to drugs and inhibitors directed at a specific target. The 
clustering of known drugs will aid in the search of potential targeted drugs with 
good structure scaffold and optimal drug properties that have higher chance to enter 
clinical trials and ultimately into the market. Due to time constraint, this is only a 
preliminary investigation of possible drug prolific regions indicating privileged 
drug-like structure scaffolds and possible drug-like property rules that differentiate 
drugs from the inhibitors with similar structure scaffolds. The main focus of this 
section will be to present the workflow of applying the hierarchical clustering 
method to cluster drugs and inhibitor in the target-specific chemical space of 
structurally similar bioactive and non-active compounds.  
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3.2.1 Data collection and method 
Ten therapeutic targets involved in various diseases were chosen for comprehensive 
coverage of different target types, including kinases (ABL1, B-Raf, FLT3, mTOR, 
SRC), G-protein coupled receptors (Beta-2 adrenoreceptor(B2AR), Dopamine D1 
receptor (DA1R)), anti-HIV target (HIV reverse transcriptase) and other classical 
therapeutic targets (ACE and COX2). The 2D structures and relevant information of 
their inhibitors were obtained from chembl database, with IC50/Ki/EC50 value less 
than 10uM. And the structurally similar bioactive compounds were also obtained 
from Chembl database, defined as Tanimoto coefficient > 0.9 against any of the 
inhibitors or drugs to that target. In the same way, the structurally similar 
non-bioactive compounds were obtained from Pubchem database, with Tanimoto 
coefficient score > 0.9 against any of the inhibitors or drugs to that target and 
structurally similar approved drugs directed at other targets were collected from 
TTD. The statistics of drugs, inhibitors, similar other approved drugs, similar 
bioactive Chembl compounds and similar non-bioactive Pubchem compounds are 
listed in Table 3.3. 
 
Table 3. 3 Overall statistics of drugs, inhibitors, structurally similar approved drugs directed 
to other drugs, similar bioactive Chembl compounds and similar non-bioactive Pubchem 
compounds to be clustered.  












ABL1 13 791 20 5529 28130 
ACE 15 659 22 5259 104838 
B2AR 20 1162 78 8048 117943 
B-Raf 9 413 6 1138 4128 
COX2 37 1917 54 11820 89985 
DA1R 24 594 136 7235 45379 
FLT3 16 939 19 7401 51665 
HIVRT 12 1810 41 9954 55903 
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mTOR 14 931 15 1796 19854 
SRC 7 2038 48 12365 87246 
 
Each compound was represented by their Pubchem fingerprint, which is an 881 bit 
binary substructure fingerprint calculated from 2D structures. Each bit shows a 
Boolean determination of the presence of, for example, an element count, a type of 
ring system, atom pairing, atom environment (nearest neighbors), etc., in a chemical 
structure. 
And the similarity is defined by Tanimoto coefficient calculated from the following 
formula. 
 
Tanimoto = AB / ( A + B - AB ) 
Where: 
      Tanimoto is the Tanimoto score, a fraction between 0 and 1. 
      AB is the count of bits set after bit-wise & of fingerprints A and B 
      A is the count of bits set in fingerprint A 
      B is the count of bits set in fingerprint B 
 
Hierarchical clustering is a clustering method that groups data over different levels 
by creating a cluster tree. It could be implemented by merging smaller clusters from 
bottom up into larger ones, or by splitting large clusters into smaller ones from top 
down. The computational complexity of the top down approach with an exhaustive 
search is O(2
n
), which makes it impossible to be applied to large data sets. The 
bottom up agglomerative approach with a complexity of O(n
3
) was used in this work. 
The cluster tree is a multilevel hierarchy, where clusters at one level are joined as 
clusters at the next level. The level of clustering can be chosen according to the 
problem under study. Hence, this clustering method was used in our study so that we 
could determine the level of clustering to best fit the idea of compound scaffold. 
 
In order to decide which clusters should be combined, a measure of dissimilarity 
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between sets of compounds is required. Accordingly, a distance matrix, which 
measures the distance between pairs of compounds, and a linkage criterion which 
specifies the dissimilarity of sets as function of the pairwise distance of compounds 
in the set were used. The distance between pairs of compounds was defined to be 
1-tanimoto coefficient. Different linkage criterion, namely complete, single and 
average linkages were all used for comparison and evaluation. 
 
The hierarchical clustering was done using the matlab linkage() function. And the 
Pubchem fingerprints were calculated using the software PaDEL-descriptor (139). 
The results of hierarchical clustering were stored in a newick format using matlab 
phytreewrite() function, which were then used as inputs to draw graphic trees 
through the online service interactive tree of life (iTol) (140).  
 
For each of the ten drug targets, hierarchical clustering method was applied and the 
resulting clustering tree was cut at Tanimoto distance of 0.6. This split of overall tree 
into sub-trees were necessary for display of the circular trees in iTol, due to its 
limited display capacity (maximum of 10000 compounds can be displayed in an iTol 
tree graph). In each sub-tree, drugs, inhibitors, other drugs, similar chembl 
compounds and similar pubchem compounds are colored differently.  
 
Additional physiochemical properties were analyzed and labeled on the distribution 
graphs, such as potency, ligand efficiency, molecular weight and logP value of the 
compound whenever available. The half maximal inhibitory concentration (IC50) 
was used to indicate the potency of a compound. Ligand efficiency (LE) is the 
measurement of binding energy of per non-hydrogen atom of the compound, which 
is related to IC50. It is defined as the ratio of Gibbs free energy to the number of 
non-hydrogen atoms of the compound and can be transformed to the following 
formula(141). 
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LE= 1.4(pIC50)/N,  
where N is the number of non-hydrogen atoms  
and pIC50 = -log(IC50).  
 
Molecular weight (MW) and logP were calculated from our own software (117). For 
easy view, the values of these properties were transformed and rounded. In particular, 
the potency value was transformed to pIC50 and rounded to the smallest integer not 
less than itself. LE was rounded and scaled to an integer accordingly. MW was 
classified into several ranges, <50, 50~150, 150~250, 250~350, and so on. LogP was 
rounded to the smallest integer not less than itself. The values of these properties 
were reflected in the heights of the labels to the outer layer of the circular tree using 
iTol and colored differently according to the type of the compound.   
 
3.2.2 Preliminary results 
Table 3.4 shows the statistics of compounds in each subtree by cutting the 
hierarchical clustering result at tanimoto distance 0.6 using the complete-linkage 
method. The subtrees containing drugs are highlighted in green and only a minority 
of subtrees for almost all the targets contain drugs. From the statistics, drugs have 
shown some clustering tendency. The possible drug concentrated regions could be 
further examined in the clustering tree results. 
 
Four figures (Figure 3.4, 3.5, 3.6, 3.7) displaying the labeled clustering results of 
FLT3 subtree ID 10 are given examples for illustration. Their potency, ligand 
efficiency, calculated cLogP and molecular weight are displayed individually in each 
figure.  
 
It looks like approved drugs may be possibly distinguished from other structurally 
similar inhibitors by either (1) higher potency than other inhibitors, (2) better LE, 
Chapter 3: Methods to learn from known drugs and inhibitors for the design of multi-target small molecule drugs 
88 
 
LogP and MW with respect to other inhibitors, (3) location in the region where there 
are other approved drugs, (4) located in the region where there are no other bioactive 
compounds around, or where the drugs have better LE than other bioactive 
compounds ( which may indicate that the drugs cannot bind to other targets 
efficiently to produce large enough negative effects and thus have a good safety 
profile).  
 
All these are only preliminary conjectures made by looking at the target-specific 
drug distribution graphs. More rigorous examinations of such graphs are required to 
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Table 3. 4 Statistics of drugs, inhibitors, structurally similar approved drugs directed to other drugs, similar bioactive Chembl compounds and similar 




























ABL1 2 8 171 498 1 3048 DA1R 8 6 129 1266 23 5232 
ABL1 5 2 268 1320 7 3840 DA1R 15 4 20 214 25 473 
ABL1 4 1 1 19 0 24 DA1R 13 3 17 376 1 4242 
ABL1 9 1 72 418 4 920 DA1R 19 3 3 60 1 196 
ABL1 10 1 195 263 1 380 DA1R 10 2 24 536 13 895 
ABL1 1 0 3 6 0 0 DA1R 18 2 22 351 21 2982 
ABL1 3 0 5 12 0 274 DA1R 6 2 3 68 3 408 
ABL1 6 0 36 79 0 1738 DA1R 9 2 61 1643 4 14797 
ABL1 7 0 7 1816 1 6930 DA1R 1 0 102 29 0 6 
ABL1 8 0 1 95 5 6 DA1R 2 0 105 2047 23 12178 
ABL1 11 0 9 82 1 739 DA1R 3 0 1 3 0 1 
ABL1 12 0 12 873 0 9430 DA1R 4 0 6 4 0 1 
ABL1 13 0 11 48 0 801 DA1R 5 0 5 52 7 380 
B-Raf 3 5 129 316 0 1106 DA1R 7 0 1 4 0 62 
B-Raf 7 3 230 373 6 1909 DA1R 11 0 1 2 1 120 
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B-Raf 6 1 0 78 0 105 DA1R 12 0 1 2 1 53 
B-Raf 1 0 4 41 0 159 DA1R 14 0 14 161 2 483 
B-Raf 2 0 25 194 0 364 DA1R 16 0 25 222 8 2040 
B-Raf 4 0 1 85 0 270 DA1R 17 0 51 45 3 131 
B-Raf 5 0 14 1 0 0 DA1R 20 0 3 150 0 699 
B-Raf 8 0 10 50 0 215 COX2 2 5 17 212 2 5435 
FLT3 10 8 216 1676 5 5873 COX2 14 5 36 371 5 3236 
FLT3 16 3 205 1171 4 5868 COX2 25 4 208 334 1 1130 
FLT3 17 2 102 71 0 271 COX2 8 3 38 183 1 2163 
FLT3 1 1 47 310 0 458 COX2 15 3 38 123 1 1676 
FLT3 4 1 42 766 3 3980 COX2 16 3 103 5347 6 28828 
FLT3 9 1 45 570 3 14950 COX2 24 3 154 803 3 11048 
FLT3 2 0 2 19 0 0 COX2 21 2 94 158 1 1031 
FLT3 3 0 1 0 0 0 COX2 26 2 19 151 0 2949 
FLT3 5 0 19 57 1 108 COX2 3 1 99 135 0 284 
FLT3 6 0 20 64 0 194 COX2 6 1 22 119 4 2846 
FLT3 7 0 43 115 0 1710 COX2 12 1 181 181 0 610 
FLT3 8 0 18 222 0 5799 COX2 17 1 86 199 1 936 
FLT3 11 0 2 3 0 10 COX2 22 1 44 134 2 1321 
FLT3 12 0 1 2 0 5 COX2 23 1 156 242 3 1207 
FLT3 13 0 66 635 1 1435 COX2 28 1 28 480 2 4664 
FLT3 14 0 69 165 1 671 COX2 1 0 167 369 2 1712 
FLT3 15 0 20 156 0 3107 COX2 4 0 17 86 0 877 
FLT3 18 0 15 1379 1 7219 COX2 5 0 37 126 0 1067 
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FLT3 19 0 6 20 0 7 COX2 7 0 6 537 0 812 
mTOR 18 5 41 190 3 1125 COX2 9 0 1 9 0 203 
mTOR 13 3 263 335 0 1504 COX2 10 0 26 103 0 201 
mTOR 1 2 75 112 0 621 COX2 11 0 63 212 1 4967 
mTOR 11 2 10 31 0 306 COX2 13 0 28 41 0 98 
mTOR 6 1 66 62 0 1715 COX2 18 0 111 88 0 1219 
mTOR 10 1 0 285 4 467 COX2 19 0 5 1 0 2 
mTOR 2 0 1 0 0 2 COX2 20 0 1 1 0 3 
mTOR 3 0 25 1 0 52 COX2 27 0 8 120 0 677 
mTOR 4 0 2 31 0 1740 COX2 29 0 59 72 12 537 
mTOR 5 0 323 466 6 2809 COX2 30 0 19 839 7 7867 
mTOR 7 0 0 0 0 2147 COX2 31 0 46 44 0 379 
mTOR 8 0 1 0 0 4198 HIVRT 29 3 388 867 6 8266 
mTOR 9 0 2 7 0 130 HIVRT 27 2 117 418 1 254 
mTOR 12 0 1 16 0 10 HIVRT 34 2 42 293 13 727 
mTOR 14 0 7 5 0 4 HIVRT 3 1 163 258 0 1297 
mTOR 15 0 108 85 1 276 HIVRT 11 1 76 146 0 382 
mTOR 16 0 5 170 1 221 HIVRT 16 1 25 225 0 435 
mTOR 17 0 1 0 0 2527 HIVRT 18 1 16 257 4 754 
SRC 2 2 318 824 0 1993 HIVRT 24 1 2 50 1 134 
SRC 9 1 0 35 0 102 HIVRT 1 0 62 195 0 233 
SRC 15 1 0 79 0 105 HIVRT 2 0 5 11 0 24 
SRC 17 1 555 2295 8 6134 HIVRT 4 0 27 47 0 1333 
SRC 18 1 439 1383 6 7927 HIVRT 5 0 15 94 3 125 
Chapter 3: Methods to learn from known drugs and inhibitors for the design of multi-target small molecule drugs 
92 
 
SRC 19 1 107 314 1 778 HIVRT 6 0 9 46 0 107 
SRC 1 0 7 29 0 632 HIVRT 7 0 61 199 0 751 
SRC 3 0 10 51 1 230 HIVRT 8 0 22 92 1 611 
SRC 4 0 151 668 4 703 HIVRT 9 0 169 415 0 3292 
SRC 5 0 14 24 0 49 HIVRT 10 0 18 35 0 339 
SRC 6 0 10 217 0 12969 HIVRT 12 0 44 60 0 131 
SRC 7 0 1 1 0 114 HIVRT 13 0 10 9 0 13 
SRC 8 0 126 704 4 1563 HIVRT 14 0 8 12 0 47 
SRC 10 0 21 47 0 1531 HIVRT 15 0 3 5 0 77 
SRC 11 0 2 37 0 591 HIVRT 17 0 19 161 1 573 
SRC 12 0 45 49 2 299 HIVRT 19 0 71 264 1 1466 
SRC 13 0 20 2490 8 9997 HIVRT 20 0 2 2 0 10 
SRC 14 0 3 247 5 466 HIVRT 21 0 1 1 1 9 
SRC 16 0 11 22 0 595 HIVRT 22 0 1 0 1 17 
SRC 20 0 31 127 0 1220 HIVRT 23 0 30 207 0 816 
SRC 21 0 125 2632 2 38225 HIVRT 25 0 105 274 0 98 
SRC 22 0 38 46 0 98 HIVRT 26 0 32 23 0 193 
SRC 23 0 4 44 7 925 HIVRT 28 0 15 50 0 114 
B2AR 1 7 62 576 18 5137 HIVRT 30 0 16 368 1 8333 
B2AR 3 4 276 272 0 1892 HIVRT 31 0 28 47 0 1532 
B2AR 10 2 29 122 4 1585 HIVRT 32 0 46 191 0 1158 
B2AR 12 2 316 845 7 2019 HIVRT 33 0 43 830 5 2802 
B2AR 15 2 44 706 15 10298 HIVRT 35 0 48 158 0 219 
B2AR 17 2 113 925 1 16568 HIVRT 36 0 71 3644 2 19231 
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B2AR 16 1 47 280 0 891 ACE 15 11 302 1816 13 32387 
B2AR 2 0 34 871 0 10182 ACE 6 1 73 1681 3 33245 
B2AR 4 0 1 2 2 13 ACE 8 1 23 58 0 655 
B2AR 5 0 16 393 0 2090 ACE 12 1 55 106 0 1256 
B2AR 6 0 5 117 0 268 ACE 14 1 41 104 0 4765 
B2AR 7 0 17 73 0 448 ACE 1 0 10 5 0 9 
B2AR 8 0 4 23 0 296 ACE 2 0 50 124 0 2502 
B2AR 9 0 7 124 8 196 ACE 3 0 4 12 1 60 
B2AR 11 0 6 127 2 971 ACE 4 0 22 24 1 428 
B2AR 13 0 4 28 0 183 ACE 5 0 3 46 3 817 
B2AR 14 0 9 9 0 4 ACE 7 0 14 187 0 7175 
B2AR 18 0 6 24 0 21 ACE 9 0 1 1 0 147 
B2AR 19 0 26 1544 11 53160 ACE 10 0 7 7 0 70 
B2AR 20 0 28 315 0 3247 ACE 11 0 7 9 0 35 
B2AR 21 0 63 113 0 412 ACE 13 0 40 1078 1 21253 
B2AR 22 0 44 340 8 4607 ACE 16 0 7 1 0 34 
B2AR 23 0 5 219 2 3455        
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Figure 3. 4 Distribution graph of FLT3 subtree ID 10, labelled according to potency values. 
The labels are colored as follows: red for Approved drug, purple for Phase III drug, pink for 
Phase II drug, blue for Phase I drug, cyan for other drugs, green for inhibitors, grey for 
similar Chembl compounds, pale grey for similar Pubchem compounds.    




Figure 3. 5 Distribution graph of FLT3 subtree ID 10, labelled according to ligand 
efficiency values. The labels are colored as follows: red for Approved drug, purple for Phase 
III drug, pink for Phase II drug, blue for Phase I drug, cyan for other drugs, green for 
inhibitors, grey for similar Chembl compounds, pale grey for similar Pubchem compounds 




Figure 3. 6 Distribution graph of FLT3 subtree ID 10, labelled according to the calculated 
clogP values. The labels are colored as follows: red for Approved drug, purple for Phase III 
drug, pink for Phase II drug, blue for Phase I drug, cyan for other drugs, green for inhibitors, 
grey for similar Chembl compounds, pale grey for similar Pubchem compounds 




Figure 3. 7 Distribution graph of FLT3 subtree ID 10, labelled according to molecular 
weight. The labels are colored as follows: red for Approved drug, purple for Phase III drug, 
pink for Phase II drug, blue for Phase I drug, cyan for other drugs, green for inhibitors, grey 
for similar Chembl compounds, pale grey for similar Pubchem compounds 
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Chapter 4. Specific multi-target modes identified by analysing 
synergistic natural product combination 
In the previous chapter, various machine learning methods and clustering method to 
learn from the structures and properties of known drugs and inhibitors for virtual 
screening and drug design have been presented. While most of the drugs and 
inhibitors are of synthetic origins based on the success of combinatorial chemistry, a 
significant portion of drugs and inhibitors nowadays are still derived from nature. 
 
Combinatorial chemistry has been an important source of creating new chemical 
entries over the past decades. However, despite the explosion of synthetic chemical 
space, people are increasingly concerned about the low yield of chemical synthesis 
to generate lead compounds. The low drug productivity has directed people‟s 
interest to natural products as drug discovery sources. Natural products derived from 
plants, microbial and marine species have a rich diversity of structures and good 
therapeutic properties. They have performed well as a major source of therapeutics 
for infectious diseases, lipid disorders, immunomodulation and cancer. Out of the 
175 FDA approved small molecule anticancer drugs, 85 of them are either natural 
products or natural derivatives(142).     
 
The information contained in natural products is of great use in drug discovery. In 
particular, natural product (NP) combinations, in many cases as combinations of 
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whole herbs or herbal extracts, may be useful sources for developing new drug 
combinations based on their novel multi-targeted mechanisms and potentially give 
clues to the design of multi-targeted drug combinations. 
 
In this chapter, synergistic natural product combinations will be analysed 
systematically. Four important questions need to be answered for assessing the 
possible contribution of synergism to the therapeutic efficacies: what are the gaps 
between the potencies of the typically studied bioactive NPs and those of drugs, 
whether synergistic combination of sub-potent NPs can sufficiently enhance their 
collective potencies to reach drug potency levels, and at what odds and by what 
molecular modes such NP combinations can be assembled.  
 
The first question was studied by analyzing the literature-reported cell-based 
potencies of 190 approved drugs and 1378 NPs of anticancer and antimicrobial 
classes. Potencies derived from cell-based assays were used instead of target-based 
and in-vivo assays for several reasons. To a certain extent, cell-based assays can 
predict some level of in-vivo activities (143, 144) and these assays have been 
successfully used for discovering therapeutic agents that entered advanced 
development stages (145). Within the same disease classes, cell-line assays are more 
mutually comparable and better reflecting overall effects of targeted actions and 
intracellular bioavailability than target-based assays. The number of NPs with 
cell-based potency data is significantly higher than those with in-vivo data. The 
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anticancer and antimicrobial classes were focused because of the availability of 
statistically significant number of cell-based activity data, the relatively comparable 
bioassays than some other therapeutic classes, and the relevance to our NP 
combination studies (67% of our studied synergistic NP combinations are from these 
two classes).  
 
The second question was addressed by evaluating 124 literature-reported synergistic 
combinations of 158 NPs with cell-based activity data available for all of the 
constituents both in individual and in the respective combination. These data are 
necessary for deriving combination index (CI) and dose reduction index (DRI, ratio 
of the effective dose in individual and in combination) to allow rigorous and 
quantitative evaluation of synergistic effects (146). The third question was probed by 
analyzing 122 molecular interaction profiles (MIPs) in 19 NP combinations with 
potencies enhanced to drug levels or by over 10-fold. These MIPs are linked to the 
potency-enhancing synergistic actions of these NP combinations, and their analysis 
reveals general molecular modes for significantly enhancing potency via collective 
modulation of specific targets and their regulators and effectors, and the 
pharmacokinetics of the active NP ingredients(73, 77). 
 
While these 122 MIPs have been individually reported in the literatures, to the best 
of our knowledge, few of them have been collectively analyzed for probing potency 
enhancing molecular modes in specific NP combinations. It is cautioned that, 
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although connections can be made between these MIPs and the synergistic 
potency-enhancing modes of the NP combinations, many of these interconnections 
are much more complicated than those analyzed here, and their activities are highly 
dynamic (147-149). The activation and the activity levels of these interconnections 
may be influenced by genetic variations (150), environmental factors (151), host‟s 
behavior (152), and therapeutic scheduling (153). Therefore, the use of these 
interconnections should be more appropriately viewed as a start to a more 
comprehensive analysis of the potency-enhancing modes in NP combinations. 
 
4.1 Method 
Experimentally determined cell-based inhibitory activities of anticancer and 
antibacterial drugs and NPs were searched from the Pubmed database (94) by using 
keyword combinations of „drug‟, „natural product‟, „herb‟, „medicinal plant‟, 
„extract‟, „ingredient‟, „GI50‟, „IC50‟, „MIC‟, “activity”, „cell-line‟, and 'in vitro". 
Cell-based inhibitory activities of 88 anticancer drugs and 102 antimicrobial drugs 
were obtained from the literatures and the NCI standard agent database. The 
approval status of these drugs was further checked against the drug data in the 
Therapeutic target database. Cell-based inhibitory activities of 1378 anticancer and 
antimicrobial NPs and 99 antimicrobial NP extracts were obtained from the 
literatures. These activities are typically given as GI50 or IC50 values against cancer 
cell-lines or MIC values against microbial cells. For drugs and NPs with multiple 
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potency data, the best potency was selected.  
 
Literature-reported synergistic NP combinations were searched from the Pubmed 
database (94) by using keyword combinations „natural product‟, „herb‟, „medicinal 
plant‟, „extract‟, „ingredient‟, „synergistic‟, „synergy‟, „synergism‟, „synergize‟, and 
„potentiate‟. The full reports of the searched articles were evaluated to select those 
synergistic NP combinations with the experimental cell-based activities available for 
all constituent NPs both as individual and in the respective combination. Although 
many NP combinations have been reported to show synergism (71, 73, 85, 86), only 
124 synergistic combinations of 158 NPs are with available cell-based activity data 
for enabling the computation of CI and DRI values. The cell-based activities of the 
constituent NPs in some of these combinations are given in terms of the percent 
inhibitory rates at particular concentrations. The CIs and DRIs of these combinations 
were computed by using the median effect equation, the multiple drug effect 

















Where D = Dose, CI: combination index, DRI: dose-reduction index 
(Dx)1 : dose of drug 1 alone to achieve 50% inhibitory effects.  
(D)1 : dose of drug 1 used in the combination to achieve 50% inhibitory effects. 
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4.2 Results and discussion 
4.2.1 Comparison of the potencies of natural products and 
drugs in cell-based assays 
Drug potency is context dependent, varying with assay, target and technology. 
Previous analysis of existing drugs has suggested that drugs in cell-based assays 
typically exhibit potencies of ≤1μM (154). Hence, in our analysis, drug potency 
levels for anticancer and antimicrobial classes were tentatively taken as 
GI50/IC50≤1μM and MIC≤1μg/mL, which are satisfied by 76% anticancer and 86% 
antimicrobial drugs respectively. It is noted that, in some cases, drug efficacy is not 
only determined by cell-based activities. Some drugs sub-potent in cell-based assays 
are nonetheless clinically efficacious by such additional mechanisms as immuo- and 
hormone modulations (155, 156). While drug potency levels can be more rigorously 
defined by consideration of these mechanisms, the possible contribution of these 
mechanisms has been studied for few drugs and NPs sub-potent in cell-based assays. 
Therefore, it is more practically feasible to tentatively focus on cell-based activities 
to enable potency analysis of statistically significant number of drugs and NPs.  
 
Figure 4.1 and 4.2 show the potency distribution profiles of 88 and 650 anticancer 
drugs and NPs, and those of 102, 609 and 99 antimicrobial drugs, NPs and NP 
extracts respectively. The median potencies of anticancer (GI50/IC50=28nM) and 
antimicrobial (MIC=0.12μg/mL) drugs are 214-fold and 104-fold higher than those 
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of anticancer (GI50/IC50=6μM) and antimicrobial (MIC=12.5μg/mL) NPs. Overall, 
25% of the anticancer and 10% of the antimicrobial NPs reach drug potency levels, 
and additional 33% of the anticancer and 37% of the antibacterial NPs are within 
10-fold range of drug potency levels (1μM<GI50/IC50≤10μM, 
1μg/mL<MIC≤10μg/mL). There is a small pool of drug level potent NPs (10-25%). 
It is noted that a significantly larger pool of NPs (47-58%) may be explored for 
designing NP combination therapies if synergistic combinations of >10-fold potency 
enhancement can be assembled at reasonable probabilities. The potencies of the NP 
extracts are mostly 100-1,000 folds lower than those of individual NPs, partly 
because the active constituents in each NP extract typically constitute a small 
percent of the contents (157). Because of their 100-1,000 fold lower potencies, NP 
extracts have been typically prescribed in g/kg (158) (159) instead of the usual 
mg/kg for individual drugs. 
 
 
Figure 4. 1 Potency distribution profiles of 88 and 650 anticancer drugs and natural 





Figure 4. 2 Potency distribution profiles of 102, 609 and 99 antibacterial drugs, natural 
products (NPs) and NP extracts. 
 
4.2.2 Synergistic natural product combinations 
Based on Chou‟s method (146), the levels of synergism in these NP combinations 
(Figure 4.3) were categorized into very strong synergism (CI<0.1), strong 
synergism (CI=0.1–0.3), synergism (CI=0.3–0.7), moderate synergism (CI=0.7–
0.85), slight synergism (CI=0.85–0.90), nearly additive (CI=0.90–1.10), slight 
antagonism (CI=1.10–1.20), and moderate antagonism (CI=1.20–1.45) respectively. 
Overall, 24% and 34% of the combinations are at the strong/very strong synergism 
and synergism levels, indicating that highly synergistic combinations can be formed 
at fair probabilities. Figure 4.4 shows the potency improvement profile of the NPs 
in these combinations, in which 4% and 19% of the NPs exhibit >100-fold and 
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10-100 fold potency improvement respectively. This suggests that >10-fold potency 
improvement is achievable at moderate probabilities. These combinations are mostly 
composed of sub-potent NPs. There are only 6 potent NPs, and 1 and 3 
combinations fully and partially composed of potent NPs. Synergism elevates the 
group potencies (potencies of all components) of 5 fully sub-potent and 2 partially 
sub-potent combinations to drug levels, and lifts the potency of 4 NPs in another 3 
sub-potent NP combinations to drug levels. Overall, the potencies of 22 (14.4%) 
sub-potent NPs and group potencies of 7 (5.6%) sub-potent combinations are 
enhanced to drug levels, suggesting that the individual and group potencies of 
sub-potent NPs can be raised to drug levels at moderate and low probabilities 
respectively. 
 
Figure 4. 3 Synergism level of 124 synergistic NP combinations. VSS, SS, S, MS, sS: very 
strong, strong, normal, moderate, slight synergism, NA: nearly additive, SA, MA: slight, 
moderate antagonism. 




Figure 4. 4 The potency improvement profile of the constituent NPs. 
 
4.2.3 Potency enhancing molecular modes of natural 
product combinations 
The molecular mechanisms of synergism of drug combinations (77) and NP 
combinations (73) can be studied from their MIPs. We conducted comprehensive 
literature search for identifying the targets and synergism-related MIPs of three NP 
combinations with collective potencies improved to drug levels, which identified 11 
targets related to the reported therapeutic effects of these combinations and 72 MIPs 
likely contributing to the potency-enhancing modes (Supplementary Table S4.1). 
The targets and potency-enhancing MIPs of two of the NP combinations are also 
summarized in Table 4.1 and 4.2. Specific potency-enhancing molecular modes 
were identified. The potencies of the principal NP in these combinations are at or 
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near drug potency levels (IC50=0.8-1.1μM, 0.94μg/mL) probably due in part to the 
multi-target activities of each principal NPs (2, 4, 5 targets respectively). Network 
models and activity assays have shown that weak inhibition of multiple targets in 
related pathways may be more efficient than strong inhibition against a single target 
(160, 161). The potencies of the companion NPs are substantially weaker 
(IC50=1.7-656μM, 5.07-251μg/mL). The potencies of all NPs in these combinations 
are significantly enhanced (mostly by >10-fold) by multi-target actions in 
modulating multiple regulators, partners and effectors of the primary targets of the 
principal and the active companion NPs (complementary actions), elevating 
intra-cellular bioavailability of the principal and the active companion NPs, and 
antagonizing the processes counteractive to the therapeutic effects of the principal 
and the active companion NPs (anti-counteractive actions).  
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Table 4. 1 The targets and potency-enhancing synergistic molecular modes of the anticancer combination of Tetraarsenic tetrasulfide, Indirubin, and 





Potency) { Dose 
Reduction Index} 
Target, Therapeutic Effect or 
Response (reference in Pubmed 
ID) 
Effect type Potency-Enhancing Synergistic 
Modes (reference in Pubmed ID) 






Degraded PML-RAR to produce 
anticancer effect (18344322) 
Growth 
inhibition,  
Indirubin blocked RAR-STAT3 
crosstalk (14959844) by reducing 
JAK/STAT3 signaling (21207415). 
Tanshinone IIA reduced RAR 
(12069693) by hindering AR 
(22175694, 22281759, 21997969). 
These complement tetraarsenic 
tetrasulfide‟s action on RAR 
Complementary 
action 
Down-regulated CDK2 in NB4 and 
NB4-R2 cells (18344322) 
Cell cycle 
regulation 
Indirubin inhibited and reduced 
CDK2 (18344322) to complement 




Upregulated RING-type E3 ligase 
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Indirubin and Tanshinone IIA 
upregulated APQ9 (18344322) to 





RAR reduction downregulated 
P53 and elevated Bcl-2 (10675490) 
to reduce apoptosis 
Counteractive 
action 
Tanshinone IIA activated p53 







Inhibited and reduced CDK2 to 




Tetraarsenic tetrasulfide reduced 
CDK2 (18344322) to complement 
indirubin's action on CDK2 
Complementary 
action 
Inhibited GSK3 to produce 




blocked VEGFR2 signaling 
(21207415) to reduce angiogenesis 





Activated AhR (20951181) which 




Tetraarsenic tetrasulfide degraded 
PML-RAR (18344322) to alleviate 






Increased Bax/Bcl-2 ratio, caspase 
3, reduced Bcl-2, mitochondrial 
membrane potential, MMPs, to 
promote apoptosis (21472292, 
22002472, 22126901) 
Apoptosis   
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Activated p53 signaling to promote 





Upregulated pP38 to enhance 
apoptosis (21165580) 
Apoptosis   
Reduced HER2, NF-κBp65, RAR 
activities (17451432) to promote 





Reduced and antagonized AR and 





pP38 upregulation (21165580) 
activated RAR (19078967, 
20080953) to promote cancer 
Counteractive 
action  
Tetraarsenic tetrasulfide degraded 
PML-RAR (18344322) to alleviate 
this counteractive action 
Anti-counteractive 
action 
Upregulated efflux transporters to 
promote Tanshinone IIA (a Pgp 




Indirubin inhibit certain efflux 
pumps (20380543) which may 
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Table 4. 2 The targets and potency-enhancing synergistic molecular modes of the anti-rotavirus combination of Theaflavin, Theaflavin-3-monogallate, 
Theaflavin-3'-monogallate, and Theaflavin-3,3' digallate (anti-rotavirus synergism reported in literature (163)).  
Natural Product [Role in 
Combination] 
(Individual Potency) 
{ Dose Reduction Index} 
Target, Therapeutic Effect or 
Response (reference in Pubmed ID) 
Effect type Potency-Enhancing Synergistic 
Modes (reference in Pubmed ID) 




Reduced JNK and P38 
phosphorelation (21184129, 
22111069) to block JNK and p38 




Other 3 components block the 
redundant Cox2 and ERK viral 
replication pathways to 








downregulated Cox2 (11103814) to 
block Cox2 mediated viral replication 




All 4 components collectively 
cover 4 redundant viral replication 









downregulated Cox2 (11103814) to 
block Cox2 mediated viral replication 




All 4 components collectively 
cover 4 redundant viral replication 








Reduced ERK phosphorelation 
(11511526) to block ERK mediated 




Other 3 components block the 
redundant JNK, P38 and Cox2 viral 








Blocked NFkB activation (16880762) 
to hinder NFkB and AkT mediated 
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Regulation of multiple regulators of the primary targets of principal NPs is 
important for elevating the collective potencies to drug levels. In two combinations, 
6 and 13 regulators of the primary targets of the principal NPs are modulated. In the 
third combination, each constituent NP targets one or two of the four redundant 
processes to collectively achieve therapeutic effects. These multi-target 
potency-enhancing modes are consistent with the reports that weak inhibition of 
multiple targets in related pathways may be more efficient than strong inhibition of a 
single target(160, 161). In these combinations, complementary actions are achieved 
by modulating the expression, upstream regulators, crosstalk/redundant signaling, 
and substrates/effectors of the targets of individual NPs. Intra-cellular bioavailability 
of NPs are enhanced by inhibiting/downregulating efflux pumps and 
upregulating/activating cell-entry transporters. Anti-counteractive actions involve 
regulation of the pathways activated by the NPs that subsequently reduce the 
therapeutic effects of the NPs. Drug efficacies are reportedly reduced by network 
robustness (164), redundancy (18), crosstalk (19), and compensatory and 
neutralizing actions (20). Our revealed potency-enhancing molecular modes of 
synergistic natural products combinations are consistent with these 
literature-reported findings and provide clues for multi-target strategies in reducing 
these negative effects. 
 
Additional potency-enhancing mechanisms were studied by analyzing 8 and 26 
MIPs in 2 and 9 combinations with the potency of the principal NP enhanced 
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by >100-fold and 10-100 fold, and 16 MIPs of 5 combinations with the potency of a 
non-principal NP improved by >10-fold respectively. (Supplementary Table S4.2, 
S4.3, S4.4) The potency of individual NPs in 13 combinations is enhanced by a 
single mechanism: enhancement of the intra-cellular bioavailability of an active NP, 
which is an extensively-explored and effective potency-enhancing strategy for those 
NPs with hindered intra-cellular bioavailability. In addition to actions on efflux and 
cell-entry transporters, intra-cellular bioavailability of NPs can be enhanced by 
regulating their metabolism, disrupting membrane structures, and the use of 
pro-drug NPs of better cell-entry abilities, The potency of individual NPs in the 
remaining 3 combination is enhanced by complementary and anti-counteractive 
modes similar to those of the three NP combinations with potencies improved to 
drug levels.  
 
Although the potencies of some of the individual NPs in these combinations are 
significantly improved, none is elevated to drug levels possibly due to low potencies 
of their principal NPs (44.6-800μg/mL with one exception) and modulation of few 
(60, 61) regulators of the targets of the principal NPs. The success rate of 
assembling sub-potent NPs into drug-level potent combinations may be significantly 
improved by careful selection of principal NPs of sufficient potency (e.g. potency 
<10μM) and the use of cooperative NPs that enhance the bioavailability and 
modulate the regulators, partners and effectors of the targets of the principal NPs.  
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4.2.4. Influence of individual genetic variations  
Combinations of sub-potent NPs heavily rely on the synergistic actions of their 
constituent NPs for improved potencies. Synergistic actions of sub-potent NP 
combinations typically involve collective modulation of a certain set of the primary 
targets and the corresponding secondary targets that regulate the primary targets or 
improve pharmacokinetics of the active NPs. Because of their heavy reliance on the 
modulation of a corresponding set of secondary targets for achieving sufficiently 
improved potency, the level of potency improvement of synergistic NP combinations 
is expected to be sensitively influenced by the genetic variations that alter the 
expression and activity level of this set of the primary targets and the corresponding 
secondary targets (150). Table 4.3 shows the expression profiles of the primary 
targets and some of the potency-enhancing secondary targets of the selected NP 
combinations in specific patient groups. The primary targets are expressed in 
42%-95% the patients and the secondary targets are expressed in 15%-100% of the 
patients in different patient groups. Significantly lower percentages of patients in 
each patient group are expected to have the right set of the primary and the 
corresponding secondary targets expressed to make them responsive to a particular 
sub-potent NP combination. Perhaps it is not a coincidence that multi-herb 
combinations have been frequently prescribed in personalized manner (165, 166) 
possibly for exploiting certain potency-enhancing modes active in specific patients. 
 




This analysis indicates the possibility of synergistically assembling sub-potent NPs 
into drug-level potent combinations, which can be achieved at low probabilities by 
the exploration of specific potency-enhancing modes that combine multi-target 
actions of the principal NPs of sufficient potency (typically within 10-fold range of 
drug potency levels) against specific disease processes with the enhancement of 
their bioavailability and/or the modulation of the regulators, effectors and 
counteractive elements of their targets. The low probabilities for assembling 
sub-potent NPs into drug-level potent combinations may arise from the difficulties 
in finding the right combination of NPs with sufficient potency and the appropriate 
and complementary potency-enhancing MIPs. Moreover, synergistic actions 
typically involve interactions with multiple sites, targets and pathways which are 
sensitively influenced by genetic(167), environmental(16), behavioral(168), and 
scheduling(169) profiles. NP combinations and related therapeutics may be better 
designed, applied and studied in personalized and environment-dependent manners 
(170, 171). The efforts in the exploration of NP combinations can be facilitated by 
expanded knowledge in the activities of NPs (172), MIPs of NPs (73), disease 
regulations, and potency-enhancing molecular modes that synergistically target key 
positive (173) and negative (17) regulatory nodes of therapeutic efficacies, and 
collectively modulate anti-targets and counter-targets (4), compensatory and 
neutralizing actions (20, 174), and transporter and enzyme mediated 
pharmacokinetic activities (175). 
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Table 4. 3 Expression profiles of the primary targets and some of the potency-enhancing secondary targets of the selected natural product combinations in 
specific patient groups 
Natural Product 
Combination 
Target Type Target Target Expression Profile in Specific Patient Groups 
Tetraarsenic tetrasulfide, 
Indirubin, and Tanshinone 
IIA 
Primary target of the principal 
ingredient 
PML-RAR Present in 95% of APL patients (12506013) 
Secondary target for enhancing the 
potency of the principal ingredient 





and Theaflavin-3,3' digallate 
Primary target of the principal 
ingredient 
JNK Expressed in 100% of patients with chronic obstructive pulmonary disease 
(20699612), pJNK expressed in 100% of multiple trauma patients (22677613) 
P38 Expressed in 82% patients with sepsis-induced acute lung injury (17581740), pP38 
expressed in 38% of multiple trauma patients (22677613) 
Secondary target involved in the 
alternative signaling that substitute 
the targeted pathway of the principal 
ingredient 
Cox2  Expressed in 100% of HBV (15218507) and 100% of HCV (17845691) patients, 
elevated in 100% of patients with HCV-induced chronic liver disease (18092051) 
ERK pERK expressed in 15% of colorectal carcinoma (17149612), 39% of 
mucoepidermoid carcinomas (12937136), 70% of breast cancer (15928662), 79% 




Primary target of the principal 
ingredient 
AR Expressed in 59% of prostate cancer (22500161), 56%-63% of breast cancer 
(18946753, 22471922), 80% of benign urothelium (22221549), 50% of benign 
stroma (22221549), 42%-71% of bladder cancer (22221549) patients 
Secondary target for enhancing the 
potency of the principal ingredient 
c-Src Expressed in 55% of metastatic breast cancer (22716210), 74% of bladder cancer 
(22353809) , 28% of hormone refractory prostate cancer patients (19447874) 
FGF1R Expressed in 69%-74% of prostate cancer (17607666), 99%-100% of breast cancer 
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(9865904, 9756721) patients 
topoisomerase 
II 
Highly expressed and amplified in 50% and 5%-7% of breast cancer (22240029, 
22555090), 31% and 26% of advanced prostate cancer (17363613), 20% and 1.5% 
of bladder cancer (11304849, 14566826) patients 
CK2 Expressed in the bone marrow of 28% of the patients with transitional cell 
carcinoma (17977715) 
EGFR Expressed in 41% of prostate cancer (22500161), 25% of breast cancer 
(22562124), 33% of triple negative breast cancer (22481575), 66%-96% of 
bladder cancer (16685269, 19171060) patients  
HER2 Expressed in 1.5%-24% of prostate cancer (19207111, 22500161), 8%-31% breast 
cancer (10550311, 11344480, 22562124), 62%-98% of bladder cancer (15839918, 
16685269) patients 
NF-kB Expressed in 53% of prostate cancer (21156016), 79% of bladder urothelial 
carcinoma (18188593), active NF-kB present in 4.4%-43% of breast cancer 
(16740744) patients 
AkT pAkT expressed in 45% prostate cancer (19389013) and 33% breast cancer 
(16464571), highly expressed in 2.6%-14.3% of patients with urothelial carcinoma 
of the urinary bladder (21707707) 
P53 Expressed in 22%-28% breast cancer (11344480), Overexpressed in 36% of 
bladder cancer (19171060) patients 
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Chapter 5: Personalized targeted theraupeutics driven by 
biomarkers 
Therapeutic Target Database has a significantly higher number (1,755) of 
literature-reported biomarkers covering more variety of disease conditions (365) 
than those in the existing biomarker databases (89-91) and thus complements those 
databases that primarily include molecular biomarkers of specific disease classes 
such as the infectious disease biomarker database (IDBD) (89, 91) or clinically 
prioritized sets (90). The more extensive coverage of potential biomarkers and the 
convenient access through ICD codes make TTD a useful tool to analyze the 
biomarker information.  
 
For personalized treatment using targeted therapeutics, the stratification of patients 
plays an essential role. In order to classify the patients according to their responses 
to treatment, biomarker information can be utilized. Chapter 5.1 is devoted to the 
analysis of biomarker information based on which a more refined disease 
classification system will be suggested. 
 
Furthermore, in chapter 5.2, based on the evaluation of non-invasive biomarkers, 
their possible application in mobile health (mhealth) technologies is also proposed 
for delivering healthcare at reduced costs and for facilitating more precise and 
personalized therapeutics.  
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5.1 More refined classification of patient 
subpopulations for personalized targeted therapeutics  
Biomarkers have been developed as non-invasive tests for early detection and 
indication of disease risks, monitoring of disease progression and recurrence, and 
classification of disease subtypes and patient subpopulations for providing the most 
appropriate treatments (176-178). As many therapies have been found to elicit 
markedly different clinical responses in individual patients(179, 180), there is a 
particular need for more biomarkers capable of predicting drug response in 
individual patients, which has led to intensive efforts in the discovery of such 
biomarkers (27, 181).  Table 5.1 gives examples of the approved and clinically 
tested biomarkers for facilitating the prescription of a particular drug to specific 
patient subpopulation.  
 
Table 5. 1 Approved and clinically tested biomarkers for facilitating the prescription of a 





Biomarker for the 
targeted therapeutics 
Patient subpopulation 













APL with PML–RARα 
t(15:17) translocation 
All trans retinoic 
acid  
Alzhemer‟s PPAR apolipoprotein E and 
TOMM40 genotypes and 
age. 
Mild cognitive impairment 
due to Alzheimer‟s disease 
 






Estrogen receptor (protein 
expression)  
ER overexpressed breast 
cancer 
Tamoxifen  
PARP  BRCA1/2 (mutation)  Breast cancer defective in 
BRCA1 or BRCA2 
Olaparib, 
veliparib  
Chronic myeloid BCR– BCR–ABL (gene Philadelphia chromosome Imatinib, 
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leukemia (CML) ABL  translocation)  and absence of BCR–ABL 






EGFR  EGFR(mutation, 
overexpression),  KRAS 
(mutation)  
EGFR overexpression 
and/or mutation, absence 







EGFR  EGFR (kinase domain 
mutation)  
EGFR mutations, absence 




ALK  ALK (rearrangements)  Rearranged ALK gene in 
NSCLC 
Crizotinib  












with persistent total hip, 
femoral neck, or lumbar 
spine BMD T-scores −1.8 








Targeted therapeutics is naturally linked to molecular-based and cell-based 
disease-classification systems (e.g. trastuzumab for HER2+ breast cancer and 
imatinib for Ph+ chronic myelogenous leukemia). From the examples of the 
approved and clinically tested drug response biomarkers in Table 5.1, it seems 
feasible to incorporate target and biomarker codes into the ICD codes for more 
refined classification of patient subpopulations responsive to a particular targeted 
therapy. To further explore this feasibility, the ICD codes for various biomarkers in 
TTD have been analyzed to check if the current disease classification ICD codes are 
able to differentiate the different subtypes of diseases and if subtype specific 
biomarkers are available.  




The results of analysis are tabulated in Table 5.2. Some known molecular and 
cell-based disease-subtypes have ICD-10 codes but many are un-coded (Table 5.2). 
Most of the common leukemia types, such as chronic lymphocytic leukemia, acute 
myelogenous leukemia and chronic myelogenous leukemia, generally have their 
subtypes coded in ICD system, while many other cancer types like breast cancer and 
lung cancer do not have coded subtypes. 
 
Though some are yet to be clinically-tested, biomarkers are available for the 
majority of the known molecular-based and cell-based disease-subtypes. Many more 
are needed for comprehensive coverage of patient sub-populations. For instance, 
HER2+ breast cancer need be further divided into HER2E-mRNA and 
luminal-mRNA subgroups based on a 302-gene multi-marker set (182).  
 
Hence, the analysis of current biomarkers in TTD and ICD classifications suggests 
that biomarker, target and drug information may be incorporated into the ICD codes 
for coding these subclasses and refining patient and drug-response sub-populations 
to facilitate the diagnosis, prescription, monitoring and management of personalized 
medicine.  
Table 5. 2 Examples of diseases and their molecular or cell-based subtypes, ICD codes 
(marked as NA if unavailable), and the availability (A) or unavailability (NA) of the 
corresponding diagnostic, prognostic and theragnostic biomarkers and if one or more 
biomarkers are in clinical use or trial 















Basal-like ER-/PR-/HER2- (NA) A A (clinical trial) A (clinical trial) 
Luminal types ER+ (C50.X + Z17.0) A (clinical use) A (clinical use) A (clinical use) 
Luminal A ER+ and low grade (NA) A A NA 
Luminal B ER+ but often high grade (NA) A A A 
Luminal ER-/PR+ (NA) A A (clinical use) A (clinical use) 
HER2+ A (clinical use) A (clinical use) A (clinical use) 
Claudin-low A NA NA 
Lung cancer 
(34.0-34.9) 
Non small cell lung carcinoma (NA) A A (clinical use) A (clinical use) 
NSCLC subtype adenocarinoma (NA) A A A 
NSCLC subtype squamous-cell lung carcinoma 
(NA) 
A A NA 
NSCLC subtype large-cell lung carcinoma (NA) NA NA NA 





 A (clinical use) A (clinical use) A (clinical use) 
Precursor B acute lymphoblastic leukemia (NA) NA A NA 
Precursor T acute lymphoblastic leukemia (NA) A NA NA 
Burkitt's leukemia (C91.A) A NA NA 





 A (clinical use) A  A  
B-cell prolymphocytic leukemia (C91.3) A NA NA 





 A (clinical use) A (clinical trial) A (clinical trial) 
Acute promyelocytic leukemia (C92.4) NA A (clinical use) A (clinical use) 
Acute myeoblastic leukemia (C92.0) A A NA 





 A (clinical use) A (clinical use) A (clinical use) 





 A NA NA 
T-cell large granular lymphocytic leukemia (NA) A NA NA 
NK cell large granular lymphocytic leukemia (NA) NA NA NA 
Other types of 
leukemia 
Adult T-cell leukemia (C91.5) A A NA 
Hairy cell leukemia (C91.4) A A A 
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However, many of the existing biomarkers are based on the profile of a single gene. 
For highly heterogenetic diseases such as cancers, single gene biomarkers are highly 
limited in their coverage of drug escape mechanisms, and multi-markers may be 
needed for more sufficient coverage of drug escape mechanisms and for more 
accurate classification of patient subpopulations in stratified and personal medicines. 
For instance, BRAF
V600E
 inhibitor dabrafenib have shown improved 
progression-free survival in BRAF
V600E
 metastatic melanoma patients (183) and 
outperformed MEK inhibitor trametinib (184) due in part to its specificity to 
BRAF
V600E
 tumors with a greater therapeutic window (185). However, drug 
resistance still emerges in dabrafenib-treated BRAF
V600E
 metastatic melanoma 
patients within months (183). These are primarily due to tumor activation of several 
BRAF inhibitor escape pathways  (185-187).Therefore, the use of a single gene 
biomarker,  BRAF
V600E
 mutation, is insufficient for classifying melanoma patient 
subpopulations responsive to dabrafenib therapy, and multi-markers need to be 
introduced for adequately covering active drug escape mechanisms in BRAF
V600E
 
metastatic melanoma patients. 
 
Apart from the literature-reported biomarkers, the profiles of various known drug 
resistance mutations (188-190) and drug response regulators (e.g. the genes 
promoting drug bypass signaling(191, 192) or hindering drug actions(193) have 
been studied for predicting drug resistance, which may be potentially explored as 
drug response biomarkers.  In particular, the collective profiles of these drug 
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response regulators may be considered as potential multi-markers for predicting 
individual patient‟s response to drug treatment. For instance, a recent study has 
shown that collective analysis of the mutational, amplification and expression 
profile of the 16 literature-reported EGFR tyrosine kinase inhibitor bypass pathway 
regulators outperforms individual profiles in classifying 53 NSCLC cell-lines 
sensitive or resistant to EGFR tyrosine kinase inhibitors gefitinib, erlotinib, and 
lapatinib (97).  
 
Therefore, from the analysis of literature, it could be envisioned that multi-markers 
which cover drug escape mechanisms could potentially be incorporated in the 
disease classification code for more personalized and stratified targeted therapies.  
 
5.2 Non-invasive biomarker and their applications to 
healthcare 
5.2.1 Background 
There have been intensifying efforts to explore mobile health (mhealth) technologies 
for delivering healthcare at reduced costs and for facilitating more precise and 
personalized medicine (194-196). These efforts have led to 73 apps endorsed 
(Supplementary Table S5.1) and additional ones reviewed (194) by the US Food 
and Drug Administration for self-diagnosis of acute diseases and monitoring of 
chronic conditions (194) based on such physiological biomarkers as body 
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temperature, pulse, electrocardiography, spirometry, blood pressure, otoscopy and 
brainwave (197, 198) (199-202))  and such conventional molecular biomarkers as 
glucose and urine protein contents (203) (200) (202).  
Although these physiological and conventional biomarkers cover many disease 
conditions, their coverage is limited particularly for cancers, infectious, respiratory, 
digestive, endocrine and nervous system diseases, as indicated by the 
disease-coverage profiles of the 73 FDA endorsed, 102 physiological and 
conventional molecular biomarkers described in the literatures (Figure 5.1). 
Additional biomarkers are needed for fulfilling the potential of mhealth 
technologies. 
 




Figure 5. 1 Disease-coverage profiles of the biomarkers. 
664 (27 in clinical trial or use) non-invasive molecular biomarkers are colored in light (deep) 
red. The 94 (13 in clinical trial or use and 73 FDA endorsed apps) physiological and 
conventional biomarkers are colored in light (deep) blue. Each leaf in the tree represents a 
specific ICD code. The details of ICD are displayed in Table 2.2. 
New genetic, proteomic and metabolomic molecular biomarkers have been 
discovered and investigated for diagnosing and monitoring diseases, directing 
treatments and predicting patient responses (178, 204-207). Of immediate relevance 
to mhealth are the hundreds of literature-reported non-invasive molecular 
biomarkers from urine, breath, saliva, tear, feces, sputum and oral mucosa samples 
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collected in TTD, which significantly expand the disease coverage as indicated by 
the disease-coverage profiles of the 664 (27 clinical trial) non-invasive molecular 
biomarkers with respect to those of the 866 (73 FDA endorsed) physiological and 
conventional biomarkers (Figure 5.1). Many biomarkers are detectable by the new 
biomarker-detection technologies that become increasingly portable, fast, 
user-friendly, inexpensive and accurate (208-213). Efforts have been directed at the 
exploration of these biomarkers and new technologies for potential mhealth 
applications (208, 211, 212, 214, 215).  
 
There are questions about whether these biomarkers combined with new 
technologies are ready for mhealth applications. One is whether the new 
technologies are sufficiently sensitive, fast and inexpensive for biomarker detection 
under the typically low sample volume and biomarker concentration conditions. 
Another is the relevance and accuracies of the literature-reported non-invasive 
molecular biomarkers for the highly-prevalent disease conditions in need of mhealth 
tools. The third is how the healthcare providers cope with the increased workload 
resulting from widespread use of mhealth devices.  
 
These questions can be probed by analysing the literature-reported biomarker 
detection capability (detection sensitivity, required sample volume, test time, and 
cost) of the new technologies combined with cellphone or the equivalent imaging 
devices, and the relevance (disease coverage and patient populations) and accuracies 
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of the literature-reported non-invasive molecular biomarkers for mhealth-based 
disease detection and monitoring. The feasibility and potential issues of workload 
reduction by developing and using a digitally-coded biomarker, disease and 
therapeutic information processing system for electronic pre-screening of the 
mhealth biomarker readings will also be discussed. 
 
5.2.2 Evaluation of new biomarker-detection technologies  
The new biomarker-detection technologies combined with cellphone or the 
equivalent imaging devices have been explored for detecting at least 14 molecular 
biomarkers including 5 non-invasive ones (Table 5.3), 50% of which can be 
detected at low concentrations (0.3-60 pg/mL and 10-20ng/mL for 4 and 3 
biomarkers respectively). Although these detectable concentrations are roughly 
10-fold higher than those of the conventional technologies (210), at least two are 
below the corresponding thresholds for non-invasive detection (210, 216). For the 
biomarkers with higher detectable concentrations, at least one is below the 
corresponding threshold for non-invasive detection (212). The detection of 64.3% of 
the biomarkers requires significantly lower sample volumes (0.5-12uL) and shorter 
detection time (10-60 min) than the typical volumes (100-300uL)(212, 217) and 
detection times (up to 4h) (210) of the conventional technologies. The cost for the 
relevant biomarker detection devices is in the range of $300-$600 US dollars ((218)). 
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Therefore, the new technologies are fairly sensitive, efficient, and inexpensive for 
detecting some of the non-invasive biomarkers in potential mhealth applications.  
 
5.2.3 The relevance and accuracies of the non-invasive 
molecular biomarkers for mhealth applications 
Analysis of the 664 literature-reported non-invasive molecular biomarker (Table 5.4) 
showed that 546 and 183 biomarkers are for the diagnosis and prognosis of 85 and 
45 disease conditions respectively. In particular, 31 (36.5%) and 14 (31.1%) disease 
conditions are covered by higher number (4-22) of biomarkers and 10 (11.8%) and 6 
(13.3%) disease conditions by clinically-validated (3 and 1 clinically-used, and 7 
and 5 in clinical trial) biomarkers. Many of these disease conditions affect large 
populations worldwide.  
 
Specifically, 2 out of 2 (100%), 3 out of 10 (33.3%) and 4 out of 15 (26.7%) acute 
disease conditions and 5 out of 11 (45.5%), 12 out of 22 (54.5%) and 12 out of 44 
(27.3%) chronic conditions with clinically-validated, higher and lower number of 
biomarkers respectively are common diseases, affecting more than 1 million US 
people or having more than 200,000 new incidences each year in US.  
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Therefore, exploration of these biomarkers in mhealth applications is expected to 
have a significant impact on improving the efficiency and quality of the 
management of these disease conditions.  
 
The accuracies of the 88 (29.7%) of the 296 diagnostic biomarkers in diagnosing 43 
disease conditions, and those of the 24 (25.5%) of the 94 prognostic biomarkers in 
prognosing 14 disease conditions have been reported (Table 5.4). The reported 
biomarker sensitivities (the likelihood for detecting diseases) and specificities (the 
probability for correctly screening negatives) (the probability that a positive signal is 
correct) is ≥75% (majority ≥85%) and ≥62.5% (majority ≥80%), and the reported 
prognosis sensitivities and specificities are ≥80% and ≥62.8% (majority ≥80%) 
respectively. Hence, the accuracies of the majority of these biomarkers are at or 
close to the ≥90% sensitivity and ≥90% specificity levels required for the good 
biomarkers (219). In comparison, the sensitivity and specificity of conventional 
screening methods used in clinic are in some cases even lower than the reported 
biomarkers (Table 5.5). Hence, these biomarkers may be potentially useful as 
pre-screening tools for identifying potential patients in need of further attention and 
test. 
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5.2.4 A digitally-coded biomarker, disease and therapeutic 
information processing system 
There are concerns about the increased workload arising from widespread use of 
mhealth devices (1). However, mhealth devices as digital tools may conveniently 
facilitate electronic pre-screening of the biomarker readings for identifying potential 
patients likely in need of further attention of the healthcare providers, which helps to 
significantly reduce the workload. A digitally-coded biomarker, disease and 
therapeutic information processing system may be developed for automatically 
receiving, processing and pre-screening the biomarker readings transmitted from 
mhealth devices, and, upon detecting alert signals, automatically informing 
healthcare providers for further evaluations and actions.  
 
It is feasible to develop such a system because some of the needed basic tools are in 
place. These include the International Classification of Diseases (ICD) codes for 
defining, studying and managing diseases and treatments,(93) the Systematized 
nomenclature of medicine (SNOMED) for clinical documentation and 
reporting(220), the Unified medical language system (UMLS) for biomedical 
terminology(221), the Therapeutic target database (TTD) biomarker and target 
information and links to the ICD and drug codes (222), and the Drugbank drug 
information (40).  
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5.2.5 Future work 
Molecular biomarker based mobile health technologies have the potential to 
significantly improve the efficiency and quality of healthcare for diverse range of 
disease conditions that cannot be solely covered by physiological and conventional 
molecular biomarkers. Some of these biomarkers are fairly accurate, sensitive and 
relevant for mhealth applications. The new technologies enable the exploration of 
these biomarkers for mhealth applications and the development of electronic 
systems for efficient management of mhealth activities. 
 
Further efforts are needed for additional information refinement and integration, and 
the determination and clinical validation of biomarker thresholds for pre-screening 
purposes. Other obstacles include the potential complications in following the 
testing protocols, and the possible issues arising from the missed recognition or 
misrecognition of disease conditions by an electronic system, lack of data security 
and lack of proper regulation standards. 
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immunoassay + mobile 
phone technologies (a 
surface acoustic wave 
transducer, a CMOS 
camera, a LED) 
low cost Y* 1 pM N/A 10 min 21725557 
Bacterial DNA N/A bacterial 
infection 
A disposable microﬂ
uidic chip with primers 
+ a ﬂuorescence 
detector + smartphone 
$350-$600 Y 760 DNA 
copies per 
uL 




blood  heart failure A disposable biomarker 
sensing element + HDR 
image acquisition 
technique 
N/A Y 60 pg/mL 150 uL 12 min 20926279 
PfHRP2 blood  malaria A disposable 
microfluidic chip + 
smartphone with 
embedded circuit 
N/A Y 16 ng/mL 0.5 uL 15 min 23689554 
lactoferrin tear disorders of the An inkjet-printed micro $1 per testing M* 0.3 mg/mL 2.5 uL 15 min 24482793 






analytical device + 
digital camera 
sheet + cost 
of digital 
camera 
HE4 urine ovarian cancer Paper-based ELISA + 
smartphone 



























M 18 pM/mL 12 uL 51 min 20512830 
adenovirus 
DNA 
N/A Viral infection A microfluidic capillary 
array + an optical signal 
ampliﬁer 
(multi-wavelength 
LEDs) + smartphone 
$180 for 
capillary array 















M 1 mg/mL uL range 60 min 24521980 






N/A tuberculosis Paper-based 
Au-nanoprobes + 
smartphone  
N/A Y N/A N/A 2 h 30 
min 
24521980 
MMP9 urine colorectal 
cancer 
Paper lateral flow assay 
+ smartphone/scanner 
$2.60 + cost 
of cellphone 
Y 1 mg/mL 5 uL N/A 24567404 
thrombin urine thrombosis Paper lateral flow assay 
+ smartphone/scanner 
$2.60 + cost 
of cellphone 
Y 1 mg/mL 5 uL N/A 24567404 
apolipoprotein 
A1 
urine bladder cancer Magnetic bead-based 





M 10 ng/mL 14.5 uL 40 min 24484673 
 
*N/A: Not available, unspecified. Y: Smartphones are used. M: Smartphones could be used alternatively.  
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Table 5. 4 Diseases covered by non-invasive molecular biomarkers 
Disease or 




















A15.0 diag P (1) Sa   81.8% 81.4%   P:World(8.6 
M),USA(9,945),UK(0.5 M) 
c Ra 
Sepsis A41.9 diag P (3) U ELISA       P:USA(660,000) a/c   
Acute hepatitis E B17.2 diag P (8) U ELISA     0.89 I:World(3 M) a Ra 
HIV infection  B20 prog P (6) U ELISA 94.0% 71.0%   P:World(35.3 M),USA(1.15 
M),UK(2.2 M) 
a/c Co 
HIV infection  B20 ther P (6) U ELISA 94.0% 71.0%   P:World(35.3 M),USA(1.15 
M),UK(2.2 M) 
a/c Co 






diag P (4) U  86.0% 80.0%   I:USA(Esophageal Cancer 
17,990) 
c Ra 
Gastric cancer C16 diag P (1) U  79.0% 100.0% 0.97 I:World(951,594),USA(21,15
5),UK(139,667) 
c Ra 
Colorectal cancer  C18-C2
1 
diag P (1), Sm (1) F, U ELISA 73.0-83.0% 82.0%   I:World(1360602),USA(134,
349),UK(447,136) 
c   
Hepatocellular 
Carcinoma 





C22.1 diag P (1) U  83.0% 79.0% 0.87 I:USA(1.67 in 100,000 ) c Ra 
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Lung cancer  C33-C3
4 
diag Sm (2) Br   84.5% 80.0%   P:USA(214,226) c   
Lung cancer 
NSCLC type  
C33-C3
4 
prog Sm (1, CT) U         P:USA(214,226) c   
Oral squamous 
cell carcinoma  
C44.02 diag Sm (2), P(2) Sa   92.3% 91.7%   I:World(640,000),USA(54,00
0) 
c   
Oral squamous 
cell carcinoma  
C44.02 prog P (1) Sa,  Sk         I:World(640,000),USA(54,00
0) 
c   
Breast cancer  C50 prog Pep (1) U ELISA       I:World(1676633),USA(232,
714),UK(464,202) 
c Co 
Ovarian cancer  C56 diag Sm (1) U ELISA 70.0% 75.0%   I:World(238,719),USA(20,87
4),UK(65,584) 
c Ra 
Prostate cancer  C61 diag Sm (1, CT), 
Pep (1, CT) 





C64 diag P (12) U ELISA 100.0% 100.0% 1 I:World(245,000),USA(65,00
0),UK(91,000) 
c   
Kidney cancer C64.9 diag P (2, CT 2) U ELISA 100.0% 100.0% 1 I:World(337860),USA(58,22
2),UK(115,252) 
c   
Bladder cancer  C67 diag P (1) U ELISA 85.7%     I:World(429,793),USA(68,63
9),UK(151,297) 
c   
Bladder cancer  C67 prog P (4) U ELISA       I:World(429,793),USA(68,63
9),UK(151,297) 
c   
Malignant 
primary brain 
C71 diag Sm (1, CT) U ELISA       I:World(256,000),USA(69,72
0),UK(57,100) 
c   




Carcinoid tumor  C75, 
E34.0 
diag Sm (1) U   35.0% 88.0%   I:World(12,000) c Ra 
Bone metastases   C79.51 prog P (1, CT), 
Pep (1, CT), 
Sm (1, CT) 
U ELISA         c   
Multiple 
myeloma 














D89.8 diag P (9) Sa, U, 
Sk 
ELISA       I:World(5500) a Ra 
Type 1 diabetes E10 diag P (2) U ELISA       P:World(11-22 M),USA(3 
M),UK(112,000) 
c Co 
Type 1 diabetes E10 prog P (1, combi 
4) 





diag P (2, combi 
261) 






diag P (7) U ELISA 81.4% 62.5%   P:World(20% - 40% of 
diabetes) 
c Co 

















E11 diag P (10) U ELISA       P:World(90 % diabetes) c Co 
Diabetes mellitus 
type 2 
E11 prog P (3) U ELISA       P:World(90 % diabetes) c Co 
Diabetes insipidus E23.2 diag P (1) U        I:World(3 per 100,000) a/c   
Aldosteronism E26.02 diag P (1) U        P:,USA(<200,000) c Ra 
Mucopolysacchari
doses  
E76 diag Sm (2) U ELISA       P:USA(200) c Ra 
Mucopolysacchari
doses  
E76 diag Sm (2) U ELISA       P:USA(200) c Ra 
Idiopathic 
hypercalciuria(IH) 
E83.52 diag P (1) U ELISA         c   
Cystic fibrosis  E84 diag Sm (2) Br   93.8% 69.2%   P:World(70,000),USA(30,00
0) 
c Ra 
Cystic fibrosis  E84 prog Sm (3) Br ELISA       P:World(70,000),USA(30,00
0) 
c Ra 
Renal light-chain E85.8 diag P (1) U  81.3% 98.0%   I:,USA(1200-3200) c Ra 
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amyloidosis (AL)  
Metabolic 
syndrome 
E88.81 prog P (1) U        P:,USA(22.9% of population) c Co 
Chronic stress  F40-F4
2 
diag P (1, CT) U ELISA 100.0%     P:World(40 M) c Co 
Enuresis F98.0 prog P (1) U        P:,USA(4-4.5% of childen) c Co 
Parkinson''s 
disease  
G20 prog Sm (1) U ELISA       P:World(10 M),USA(1 
M),UK(6.7 M) 
c Co 
Multiple sclerosis G35 diag P (1) U ELISA       P:World(30 in 100 
000),USA(400,000),UK(80 in 
100 000) 
a/c*   
Obstructive sleep 
apnea syndrome  
G47.33 diag Sm (1) Sa         P:World(3%-7%),USA( 4% in 
men, 2% in women) 
c Co 
Encephalopathy G93.4 diag Sm (1), P (1) U ELISA 99.0% 97.0%     a   
Encephalopathy G93.4 prog Sm (1), P (1) U ELISA         a   
Ocular allergy  H00-H5
9 
diag Pep (2), P (3) T ELISA       P:World(2 M) a*/c Ra 
Ocular allergy  H00-H5
9 
prog P (1) T ELISA       P:World(2 M) a*/c Ra 
Dry eye disease  H16.22
9 
diag Pep (2, CT 
1), P (19) 
T ELISA 85.0% 94.0%   P:World(4.88 M) c   
Dry eye disease  H16.22
9 
prog Pep (2), P (1) T ELISA       P:World(4.88 M) c   
Glaucoma  H40-H4 diag P (1) Eye         P:World(60 M),USA(2.2 M) a/c* Co 













ther Sm (1) Br         P:,USA(260,000) a*/c   
Atrial fibrillation I48 diag Sm (1) U        P:World(33.5 M),USA(2.66 
M) 
a/c Co 
Heart failure  I50 diag P (1, CU), Sm 
(1) 
Hair, U         P:World(26 M),USA(5.1 
M),UK(3.5 M) 
a/c Co 





































Asthma  J45 diag Sm (4), P (1), 
Cell (2) 
Br, Sp ELISA 73.6-86.0% 88.0%   P:World(235 M),USA(25 
M),UK(30 M) 
c Co 
Asthma  J45 prog Sm (2), P (1) 
Sm+P (1, 
CT), Cell (1), 
Sm+Cell (1) 























prog P (2) U ELISA ~82% ~68% 0.8 I:USA(680,000) a*/c Co 
Crohn's disease K50 prog P (2) U        P:World(0.1-16 in 100,000 ) c Ra 
Inflammatory 
Bowel Disease  
K50,K5
1 
diag P (12, CU 2), 
Sm (1) 




  P:World( 0.396% 
population),USA(1.4 
c Co 





Bowel Disease  
K50,K5
1 









Bowel Disease  
K50,K5
1 




Acute pancreatitis K85 diag P (8) U ELISA 100.0% 96.0%   I:USA(32-44 in 100,000) a   




diag P (2) U  81.0% 97.0%   I:USA(13-45 acute + 5-12 
xhronic in 100,000) 
a/c   
Psoriasis  L40 diag P (2), miR 
(4), cell (1) 
















diag P (3) U ELISA 74.6% 85.7% 0.84   c   
Osteoarthritis  M15-M
19,M47 
diag Sm (1), Pep 
(1), Modified 
Pep (2, CT 1) 
U         P:World(26.9 M) c Co 





prog Sm (1), Pep 
(3), Modified 
Pep (2) 
U         P:World(26.9 M) c Co 
Knee 
osteoarthritis 
M17  diag P (1) U ELISA         c   
Kawasaki disease M30.3 diag P (14) U ELISA ~92% ~95% 0.98 P:USA(9-19 in 100,000 




M32 diag P (2) U ELISA       P:USA(161,000-322,000) c   
Systemic lupus 
erytematosus 
M32 prog P (3) U ELISA ~70% ~89% 0.76 P:USA(161,000-322,000) c   
Lupus nephritis  M32.1, 
N08.5 
diag P (3) U ELISA 88.5% 46.3% 0.73   c   
Lupus nephritis  M32.1, 
N08.5 
prog P (5, combi 
3), miR (2) 












diag P (1) U ELISA       P:USA(70,000) c Ra 
Crescentic N00.7, diag P (1) U ELISA 91.7% 90.2%     a   














N02.2 diag P (1) U ELISA 86.0%     I:USA(2000) c Ra 
IgA nephritis N02.8 diag P (65) U ELISA 81.7% 73.4%   P:USA(1 in 100,000) c Ra 
IgA nephritis N02.8 prog P (9) U ELISA 100.0% 100.0% 1 P:USA(1 in 100,000) c Ra 




N03.2 prog P (1) U ELISA 87.5% 90.5% 0.95   c   
Nephrotic 
syndrome 















N04.0 diag P (1) U ELISA       P:USA(1.5-2.3 per 100,000) a Ra 
Idiopathic N04.9 diag P (1) U          a   








N04.9 prog P (1) U          a   
Vesicoureteral 
Reflux 
N13.7 diag P (2) U ELISA 67.0% 85.0% 0.77 P:World(1%-2% of children) c   
Vesicoureteral 
Reflux 
N13.7 prog P (2) U ELISA 81.2% 85.0% 0.88 P:World(1%-2% of children) c   
Contrast-induced 
nephropathy 
N14.1 diag P (18) U ELISA 73.0% 100.0% 0.92 P:World(<2% of population) a   
Contrast-induced 
nephropathy 
N14.1 prog P (2) U ELISA 80.0% 75.0%   P:World(<2% of population) a   
Balkan endemic 
nephropathy 










N17 diag P (15, CU 2, 
CT 3) 
U ELISA 69-100%, 
73-100% 










N18.9 diag P (2) U ELISA       P:World(8-16% of 
population),USA(20 million) 
c Co 
Chronic kidney N18.9 prog P (18) U ELISA       P:World(8-16% of c Co 
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disease population),USA(20 million) 
Kidney calculi N20.0 diag P (20) U        P:USA(1 in 11) c Co 
Urolithiasis N21.0-
N21.9 
diag P (3) U ELISA 90.0% 68.0%   P:USA( 7% of women and 




prog P (1) U ELISA       P:USA( 7% of women and 
12% of men) 
c Co 
Interstitial cystitis N30.10, 
N30.11 
diag P (7), Sm (2) U ELISA 70.0% 72.4%   P:USA( 8 million women ) c Co 
Overactive 
bladder  
N32.81 diag Sm (1), P (4) U ELISA       P:World(33 M),USA(22 M) c Co 
Overactive 
bladder  
N32.81 prog Sm (1), P (4) U ELISA       P:World(33 M),USA(22 M) c Co 
Urinary tract 
infection 
N39.0 diag P (1) U ELISA       P:USA(1 in 5 women) a*/c Co 
Dents disease N39.8 diag P (66) U        P:World(250) c Ra 
Endometriosis N80 diag P (1) U        P:World(6û10% of women) c Co 
Pre-eclampsia O11,O1
4 









y dysplasia  
P27.1 diag Sm (3), Pep 
(1, CT) 
Br, U ELISA 50-85%  
61.1-90.0% 
  I:World(12,000) c Ra 
Necrotizing 
enterocolitis 
P77 diag P (3) U ELISA       P:World(1-3 in 1,000 
infants) 
a Ra 















Q61 diag Sm (1), P (5) U ELISA       P:World(12.5 
million),USA(0.6 M) 
c   
Congenital 
hydronephrosis 









S06 prog P (1) U ELISA 90.0% 62.8% 0.78 P:USA(823.7 in 100,000) a/c Co 
Rejection of renal 
transplants  
T86.1 diag P (5), P+Pep 
(1) 




    a   
Rejection of renal 
transplants  
T86.1 prog P (1) U ELISA 84-87% 95-96%     a   
diag:diagnostic,prog:prognostic,ther,theragnostic     
P:Protein, Sm:Small molecule, Pep: Peptide, miR:microRNA, CU:Clinical use, CT:Clinical trial, 
combi:combination 
Breath: Br, Feces:F, Saliva: Sa, Skin:Sk, Sputum:Sp, Tears: T,Urine:U,  
A: acute, C:Chronic 
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Co:Common, Ra:Rare     
 
  
Chapter 5: Personalized targeted theraupeutics driven by biomarkers 
152 
 
Table 5. 5 Conventional test performance 





Cervical Cancer mild dysplasia Pap smear test 68% 75% diagnostic   tissue 
Cervical Cancer moderate/severe 
dysplasia  
Pap smear test 70% - 80% 95% diagnostic   tissue 
Cervical Cancer moderate dysplasia Self-collected HPV DNA testing 86.20% 80.70% diagnostic DNA tissue 
Cervical Cancer severe dysplasia Self-collected HPV DNA testing 86.10% 79.50% diagnostic DNA tissue 
breast cancer Mammography     diagnostic   tissue 
colorectal cancer Fecal Occult Blood Test (FOBT) 88.20% 89.70% diagnostic   stool 
advanced neoplasm Fecal Occult Blood Test (FOBT) 61.50% 91.40% diagnostic   stool 
proximal colon cancer  fecal immunochemical testing (FIT) 58.30% 94.50% diagnostic   stool 
colorectal cancer Stool DNA testing 51.60%   diagnostic DNA stool 
lung cancer low-dose helical computed tomography (LDCT) 40% -95%   diagnostic   body 
lung cancer chest radiography     diagnostic   body 
Neuroblastoma vanillylmandelic acid (VMA) and homovanillic 
acid(HVA) levels 
40% -80% 99.90% diagnostic small 
molecule 
urine 
ovarian cancer Transvaginal ultrasonography (or transvaginal 
sonography) 
  84.90% diagnostic   body 
ovarian cancer  CA125  20% -57% 95% diagnostic protein serum 
prostate cancer Digital Rectal Exam 16.70%   diagnostic   body 
prostatic carcinoma  Transrectal Ultrasound  71%-92% 49%-79% diagnostic   body 
prostate cancer PSA 71% 91% prognostic protein serum 
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stomach cancer pepsinogen levels I and II (PGI and PGII) 84.60% 73.50% diagnostic protein serum 
stomach cancer Barium-meal gastric photofluorography   67%-80% diagnostic   body 
stomach cancer Gastric endoscopy     diagnostic   body 
 coronary heart disease cholesterol 83.30% 96.30% diagnostic small 
molecule 
blood 
type 2 diabetes hemoglobin A1c 66% 98% diagnostic protein blood 
diabetic retinopathy glucose  75%-80%  75%-80% diagnostic small 
molecule 
plasma 
diabetic retinopathy fasting plasma glucose  75%-80%  75%-80% diagnostic small 
molecule 
plasma 
diabetic retinopathy hemoglobin A1c   75%-80%  75%-80% diagnostic protein blood 
hypertension blood pressure 100% 70.40% diagnostic   body 
Phenylketonuria PKU screening test 100% 51% diagnostic   blood 
Phenylketonuria PKU screening test 100% 98% diagnostic   blood 
thyroid dysfunction Thyroid-Stimulating Hormone (TSH)  89-95% 90-96% diagnostic small 
molecule 
serum 
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Chapter 6: Concluding remarks 
The modern rational drug discovery process starts with the hypothesis that 
modulation of certain targets may exert therapeutic value and therapeutics directed 
at those targets are developed to combat diseases. The identification and validation 
of target led by the knowledge of the molecular basis of diseases in the early steps of 
drug discovery paves the way for the drug development directed at the specific 
targets. In comparison with the traditional drugs, rationally designed drugs directed 
at specific targets show more promising efficacy profile and fewer toxic side effects. 
 
Although our knowledge of the underlying mechanisms of diseases is increasing, 
modern drug discovery remains a lengthy and costly process. Ways to enhance its 
productivity are highly desired. In this big data era, the large and complex collection 
of various targeted therapeutics data call for efficient data management and analysis 
methods. In this thesis, efforts to update TTD for store, integrate and retrieve 
reliable data of therapeutics date and various bioinformatics methods to analyse 
these data for drug discovery were reported.  
 
In Chapter 2, various aspects regarding the therapeutics data in TTD were presented, 
such as data collection methods, data sources and ways to access data in TTD. The 
search tools for using the International Classification of Disease ICD-10-CM and 
ICD-9-CM codes were added to link and retrieve the target, biomarker and drug 
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information (currently enabling the search of almost 900 targets, 1800 biomarkers 
and 6000 drugs related to 900 disease conditions). Information of almost 1800 
biomarkers for 300 disease conditions were newly added to the TTD in the latest 
update. The data contents were significantly expanded to cover >2300 targets (388 
successful and 461 clinical trial targets), 20 600 drugs (2003 approved and 3147 
clinical trial drugs) and 20 000 multitarget agents against almost 400 target-pairs. 
The updated TTD database enables more convenient data access and will serve the 
bench-to-clinic communities better by facilitating the discovery, investigation, 
application, monitoring and management of targeted therapeutics. 
 
Chapter 3 described several methods to learn from the properties and structures of 
known drugs and inhibitors for better design of multi-target small molecule drugs. In 
chapter 3.1, the evaluation of three VS methods showed reasonably good 
dual-inhibitor yields consistently in all models and the dual-inhibitor yields of the 
target pairs at all similarity levels were comparable among the three methods. The 
false hit rate of combi-SVM method was comparable and in some cases better than 
the false hit rate of other VS tools reported in literature. But the dual inhibitor yields 
tended to show larger variations at decreasing similarity between the drug-binding 
domains of the target pairs, suggesting that it was more difficult to produce 
consistent dual inhibitor yields for lower similarity target pairs. And the selectivity 
of all three methods against individual-target inhibitors tended to be significantly 
decreased when similarity level of the target pairs is increased. Based on the 
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evaluation results, the VS tools were good at predicting dual-inhibitors with 
reasonably high yields and low false hit rate. But the target selectivity performance 
of these VS tools needed to be further improved, especially in target pairs with high 
similarity levels in their binding sites.   
 
The VS tools developed in Chapter 3.1 could identify virtual hits from the large 
chemical libraries, but from hit to lead and from lead to drugs, more methods were 
needed to shorten the process and to increase the success rate. In chapter 3.2, a 
hierarchical clustering method was proposed to cluster known drugs in the target 
specific chemical space spanned by compounds from large chemical libraries. 
Preliminary investigation seemed to hint that there could be some drug prolific 
regions showing privileged drug like structure scaffold and drugs tended to have 
certain properties in comparison with the inhibitors with similar structure scaffold. 
This method will be further evaluated on more datasets to generate more reliable 
rules to predict compounds of good structure scaffold and optimal drug properties 
that could have higher chance to enter clinical trials and become drugs. 
 
A systematic analysis of natural product combinations was detailed in Chapter 4 to 
learn from nature in search of novel multi-target mechanisms. Through analysing 
124 synergistic natural product combinations, and 122 molecular interaction profiles 
of the 19 natural product combinations with collective potency enhanced to drug 
level or by >10-fold, it was found that most of the evaluated natural products and 
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combinations were sub-potent to drugs. And sub-potent natural products could be 
assembled into combinations of drug level potency, though at relatively low 
probabilities. Distinguished multi-target modes that modulating primary targets, 
their regulators and effectors, and intracellular availability of the active natural 
products were identified and could shed light to the design of multi-target 
therapeutics. 
 
To reflect the current shift of drug development focus to more personalised targeted 
therapeutics, the biomarker information was systematically analyzed in Chapter 5. 
The analysis of current biomarkers in TTD and ICD classifications suggested that 
biomarker (especially multi-markers), target and drug information may be 
incorporated into the ICD codes for coding these subclasses and refining patient and 
drug-response sub-populations. In addition, evaluation of non-invasive biomarkers 
in literature suggested that molecular biomarker based mobile health technologies 
have the potential to significantly improve the efficiency and quality of healthcare 
for diverse range of disease conditions. Many non-invasive biomarkers are fairly 
accurate, sensitive and relevant for mhealth applications. 
 
The discovery and application of targeted therapeutics increasingly involve 
collective efforts from multiple bench-to-clinic communities and are moving more 
and more towards stratified and personalized medicine. The drug, target, biomarker, 
and other relevant chemical, biological, pharmaceutical and clinical data need to be 
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more integrated and easily accessible by the multiple bench-to-clinic communities. 
Continuous efforts to develop and improve bioinformatics methods for analyzing 
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Supplementary Table S4.1: Targets and potency-enhancing synergistic molecular modes in 3 fully or partially sub-potent natural product 
combinations with group potencies improved to drug levels. 





Therapeutic Effect or 
Response 
Effect type Synergistic Action for Effect or 
Against Negative Response 
Type of  Synergism 






6.88 degraded the PML-RAR  oncoprotein 
leading to anticancer effect 
(18344322),  which may also hinder 
the possible antagonistic effect of RAR 
on TGF-alpha induced growth 
inhibition (12527889) 
Anticancer, growth 
inhibition, via RAR 
Indirubin blocked VEGFR2-mediated 
JAK/STAT3 signaling (21207415), which 
partially hindered RAR-STAT3 crosstalk 
and its promotion of apoptosis 
resistance (14959844) and transcription 
activation (15044588), thereby 




     Tanshinone IIA reduced and antagonized 
androgen receptor (AR) (22175694, 
22281759, 21997969) to hinders its 
effect on the upregulation of RAR 






tetraarsenic tetrasulfide's action in 
reducing PML-RAR  
   down-regulated CDK2 in NB4 and 
NB4-R2 cells (18344322) 
Anticancer, cell 
cycle regulation 
Indirubin inhibited and down-regulated 
CDK2 (18344322) to complement 
tetraarsenic tetrasulfide's action in 
reducing CDK2  
Complementary 
action 
   upregulated RING-type E3 ligase c-CBL, 





   tetraarsenic tetrasulfide  tranported 
into tumor cell by AQP9 (18344322) 
bioavailability Indirubin upregulated APQ9 (18344322) 




     Tanshinone IIA (T) upregulated APQ9 




   Reduction in RAR alpha may lead to 
P53 downregulation and Bcl-2 
upregulation, thereby coutering 




Tanshinone IIA's activation of p53 
signaling (21997969) may help against 
thie counteractive action 
Anti-counteractive 
action 
       
Indirubin (>3uM) Cooperative >9.38 inhibited and down-regulated CDK2, 
leading to anticancer effect (18344322) 
Anticancer, cell 
cycle regulation 
Tetraarsenic tetrasulfide reduced CDK2 






indirubin's action on CDK2 
   inhibited GSK-3, thereby blocked its 





   inhibited angiogenesis via blocking 
VEGFR2-mediated JAK/STAT3 signaling 
(21207415), which also partially 
hindered RAR-STAT3 crosstalk and its 
action on apoptosis resistance 
(14959844) and transcription 










   activated AhR (20951181), and AhR 
activation may lead to the activation of 
RAR alpha in the absence of ligand, 





via RAR regulator 
Tetraarsenic tetrasulfide degraded the 
PML-RAR  oncoprotein  (18344322), 




       
Tanshinone IIA (>3uM) Cooperative >9.38 increased Bax/Bcl-2 ratio and caspase 
3, decreased Bcl-2, mitochondrial 
membrane potential, MMPs and CD31, 
leading to anticancer apoptosis effects 







   activated p53 signaling to promote 





   reduced survivin, ERCC1 and LRP via 
upregulation of phospho-P38, leading 





   reduced HER2, NF-κBp65 and LC3-II, 
leading to anticancer effect particularly 
against breast cancer (22246196), 
NF-κBp65 downregulation further 
hindered the effect of the binding of 
NF-κBp65 and RAR alpha on 
transcriptional regulaiton (17451432), 
which further contributes the 
ingredient's anticancer effects 
Anticancer, 
apoptosis, growth 






   reduced and antagonized androgen 
receptor (AR) and induced apoptosis, 
leading to anticancer effect against 





   upregulated phospho-P38 (21165580), 
which may help directing RAR alpha to 








subsequently cooperate with other 
cancer proteins for effective 
transcriptional activity in certain 
cancers (20080953), thereby 
countering anticancer effect 
   increased efflux transporters, which 
may help effluxing the ingredient (a 
Pgp substrate), thereby lowering its 




Indirubin may inhibit certain efflux pump 




       
       
Theaflavin (0.943ug/mL) Main 
therapeutic 
component 
9.33 Rotavirus activated JNK and p38 
signaling pathways for enhanced viral 
replication (16928761), theaflavin 
reduced JNK and P38 phosphorelation 
(21184129, 22111069), which hinders 
viral replication and leads to virus 
neutralisation 
Antiviral, against 




The four ingredients target 4 redundant 
viral relication regulators, leading to 
strong synergistic antiviral activity, such 
activity is further enhanced by athways 








Cooperative 2489 Rotavirus activated Cox2 to mediate 
viral infection at a postbinding step 




downregulated Cox2 (11103814), 
Antiviral, against 








which hinders viral replication and 
leads to virus neutralisation 
theaflavin-3'-monogallate 
(5.07ug/mL) 
Cooperative 50.2 Rotavirus activated Cox2 to mediate 
viral infection at a postbinding step 




downregulated Cox2 (11103814), 
which hinders viral replication and 
leads to virus neutralisation 
Antiviral, against 







Cooperative 54.6 Rotavirus activated ERK signaling 
pathways for enhanced viral replication 
(17689685), theaflavin-3,3' digallate 
reduced ERK phosphorelation 
(11511526), which hinders viral 
replication and leads to virus 
neutralisation 
Antiviral, against 





   Rotavirus activated NFkB and AkT 
signaling pathways to supress 
virus-induced cellular apoptosis and 
facilitate viral growth (20392855), 
theaflavin-3,3'-digallate  blocked 
Antiviral, against 






NFkB activation (16880762) thereby 
hindered viral growth 
All four ingredients   Rotavirus's  entry into cells is partly 
facilitated by integrin, and rotavirus 
replication upregulated alpha2beta1 
and beta2 integrins via activation of 
PI3K pathways, leading to further 
enhanced viral entry (17942548),  
theaflavins educed PI3K and pAkT 
(14743383), thereby reduced the 




   Possible Antivriral Effect    
theaflavin-3,3' digallate 
(5.51ug/mL) 
  Rotavirus's  entry into cells is partly 
facilitated by haemagglutinin 
(15165605), theaflavin-3,3' digallate 
inhibited haemagglutinin of influenza 
virus (8215301), if it also inhibits 
haemagglutinin of rotavirus,  
theaflavin-3,3' digallate may hinder the 





       




wedelolactone (0.8uM) Main 
therapeutic 
component 
63.5 Potent androgen receptor (AR) 
antagonist (IC50 0.2uM) (17942463) 
Anticancer, growth 
inhibitin, via AR  
indole-3-carboxylaldehyde's assumed AR 
downregulation (17942463) 
complements wedelolactone's AR 
antagonism, leading to synergism 
Complementary 
action 
     luteolin reduced AR expression in dose 
and time dependent manner 
(18008333), which complements  




     luteolin inhibited c-Src activities 
(20215519), which hinders c-Src 
mediatedenhancement of AR activity 
and AR transactivation function 
(21135112, 18223692), thereby 
complementing  wedelolactone's AR 
antagonism, leading  to synergism 
Complementary 
action 
     luteolin downregulated FGF1R signaling 
(22269172) to hinder its crosstalk with 
AR and stimulation of AR activity 
(21465482), which complements  







     luteolin inhibited topoisomerase II 
(19149659) to hinder AR and 
topoisomerase II beta  binding 
mediated oncogenic rearrangement and 
DNA repair (20601956. 21385925), 
thereby complementing  




     apigenin inhibited CK2 (21871133), CK2 
inhibition lead to AR downregulation in 
prostate cancer cells (17044081), 
thereby complementing wedelolactone's 
AR antagonism, leading to synergism 
Complementary 
action 
     apigenin reduced EGFR and HER2 
expression (21196218) to hinder EGFR 
and HER2 mediated AR activation and 
prostate cancer progression (19318561), 
thereby complementing wedelolactone's 
AR antagonism, leading to synergism 
Complementary 
action 
     apigenin inhibited NF-κB activation 
(21142820) to hinder its promotion of 
AR expression in prostate cancer cells 
(18701501, 19628766), thereby 






antagonism, leading to synergism 
     apigenin activated P53 (22227579), 
which helps downregulating AR in 
prostate cancer (18084622)  
Complementary 
action 
     luteolin and apigenin each suppressed 
Akt  activation (20655656, 22084167), 
which hinders AkT-mediated AR 
upregulation in prostate cancer 
(21317204), thereby complementing 




     luteolin and apigenin each reduced CDK6 
activity (20655656, 16648554), which 
hinders CDK6-mediated enhancement of 
AR transcriptional activity in prostate 
cancer cells (15790678) to complement 






     luteolin and apigenin each inhibited 
GSK-3β (IC50 1.5 and 1.9uM) 
(21443429),   GSK-3β inhibition helps 
AR export from cell nucleus thereby 
diminishing its effects (21980429), which 




     luteolin and apigenin each inhibited 
HDAC (IC50 50-100 and  20-40 uM) 
(21074525, 22006862) to hinder HDAC's  
facilitating action on AR function in 
hormone-sensitive and castrate-resistant 
prostate cancer (19176386), thereby 
complementing  wedelolactone's AR 
antagonism, leading to synergism 
Complementary 
action 
   inhibited the activity of DNA 





   inhibited IKK leading to reduced 





   inhibited trypsin (12722155), trypsin 
may have tumor suppressive activity 




apigenin activated P53 (22227579), 
which helps downregulating AR in 






hindered by wedelolactone 
       
indole-3-carboxylaldehyde 
(656uM) 
Cooperative 15238 indole-3-carboxylaldehyde's structural 
analog indole-3-carbinol (I3C) forms 
DIM under acidic conditions; with a 
more stable and more potent 
anticancer activity, I3C and DIM 
antagonized androgen binding to AR 
and down-regulated AR in PCa cells 
(17942463). It has been speculated 
that indole-3-carboxylaldehyde may 
have similar activities (17942463) 
Anticancer, growth 





       
luteolin (1.72uM) Cooperative 3.13 AR  antagonist (IC50 2.4uM) 
(17942463) 
Anticancer, growth 
inhibition, via AR 
antagonism 
indole-3-carboxylaldehyde's assumed AR 
downregulation (17942463) 
complements luteolin's AR antagonism, 
leading to synergism 
Complementary 
action 
   reduced AR expression in dose and 
time dependent manner (18008333), 
which complements its AR antagonist 
activity 
Anticancer, growth 






   suppressed Akt phosphorylation and 
activation (20655656), AR levels are 
upregulated by Akt in prostate cancer 
(21317204) and AR induces prostate 
cancer cell proliferation through mTOR 
activation (16885382), luteolin thus 
hinders AkT-mediated proliferation and 
survival, and helps containing AR levels 
Anticancer, growth 
inhibition and 






   reduced CDK4/6 activity  (20655656), 
CDK6 associates with AR and enhances 
its transcriptional activity in prostate 
cancer cells (15790678), luteolin may 
thus  hinders CDK4/6 mediated 
cell-cycle progression and AR 
expression 
Anticancer, growth 
inhibition and cell 
cycle regulation, via 
dual AR and cell 
cycle regulator 
.  
   inhibited c-Src activities (20215519), 
which hinders c-Src mediated growth 
signaling (18045060) and 
enhancement of AR activity and AR 
transactivation function (21135112, 
18223692) 
Anticancer, growth 






   GSK-3β inhibitor (IC50 1.5uM) 
(21443429),   GSK-3β inhibition helps 
AR export from cell nucleus thereby 
Anticancer, growth 






diminishing its effects (21980429), 
which complements AR antagonism 
   HDAC inhibitor (IC50 50-100uM) 
(21074525), which hinders HDAC's 
transcription regulation (19383284) 
and facilitating action on AR function in 
hormone-sensitive and 
castrate-resistant prostate cancer 
(19176386), thereby complementing 
AR antagonism 
Anticancer, growth 





   downregulated FGF1R signaling 
(22269172), which hinders its growth 
and survival signaling (19183230) and 
its crosstalk with AR and stimulation of 
AR activity (21465482) 
Anticancer, growth 






   inhibited topoisomerases I and II 
(19149659), which hinders AR and 
topoisomerase II beta  binding 
mediated oncogenic rearrangement 
and DNA repair (20601956. 21385925) 
Anticancer, growth 
and survival 










activation reduced growth of prostate 
cancer cells (19347029) 
inhibition 
   inhibited proteasome (22292765), 





   downregulated Cyclin D1 (20655656), 
AR is strongly suppressed by cyclin D1 
(21212260), luteolin may thus both 









   activated P38 (22073986, 21762691), 
P38 activation may facilitate 
androgen-independent AR activation 
(19151763), which counters luteolin's 





       
apigenin (3.02uM) Cooperative 250 AR  antagonist (IC50 9.8uM) 
(17942463) 
Anticancer, growth 
inhibition, via AR 
antagonism 
indole-3-carboxylaldehyde's assumed AR 
downregulation (17942463) 
complements apigenin's AR antagonism, 






     luteolin reduced AR expression in dose 
and time dependent manner 
(18008333), which complements  




   inhibited CK2 (21871133), CK2 
inhibition lead to AR downregulation in 
prostate cancer cells (17044081), 
thereby complementing its AR 
antagonism activity 
Anticancer, growth 
inhibition, via AR 
reduction 
  
   reduced EGFR and HER2 expression 
(21196218) to hinder EGFR and HER2 
mediated AR activation and prostate 
cancer progression (19318561) and 
HER2 signaling in prostate cancer 
(15769631) 
Anticancer, growth 





   inactivated Akt (22084167), AR levels 
are upregulated by Akt in prostate 
cancer (21317204) and AR induces 
prostate cancer cell proliferation 
through mTOR activation (16885382), 
luteolin thus hinders AkT-mediated 
proliferation and survival, and helps 
containing AR levels 
Anticancer, growth 
inhibition and 









   reduced CDK2/4/6 activity  
(16648554), CDK6 associates with AR 
and enhances its transcriptional 
activity in prostate cancer cells 
(15790678), apigenin may thus  
hinders CDK4/6 mediated cell-cycle 
progression and AR expression 
Anticancer, growth 
inhibition and cell 
cycle regulation, via 
dual AR and cell 
cycle regulator 
  
   GSK-3β inhibitor (IC50 1.9uM) 
(21443429),   GSK-3β inhibition helps 
AR export from cell nucleus thereby 
diminishing its effects (21980429), 
which complements AR antagonism 
Anticancer, growth 
inhibition, via AR 
regulator  
  
   HDAC inhibitor (IC50 20-40uM) 
(22006862), which hinders HDAC's 
transcription regulation (19383284) 
and facilitating action on AR function in 
hormone-sensitive and 
castrate-resistant prostate cancer 
(19176386), thereby complementing 
AR antagonism 
Anticancer, growth 





   inhibited NF-κB activation (21142820) 
to hinder its promotion of AR 
expression in prostate cancer cells 
(18701501, 19628766), thereby 
Anticancer, growth 






complmenting its AR antagonistic 
effect 
   activated P53 (22227579), which 
enhances P53 mediated tumor 
supressive activity in prostate cancer 
(21227058[), and helps downregulating 
AR in prostate cancer (18084622) and 
compensating for the reduced P53 
activation due to AR downregulation 
Anticancer, growth 





   downregulated Cox-2 expression 
(20691240) to hinder Cox-2's 





   increased Bax/Bcl-2 ratio, caspase 3 
and cytochrome C, decreased Bcl-2, 





   activated AMPK (21538580), AMPK 
activation reduced growth of prostate 









   inhibited proteasome (22292765), 
which may induce apoptosis 





   induced Hsp27 phosphorelation 
(21364669), Hsp27 mediated 
repression of AR function in prostate 
cancer cells (19767773), but promoted 
IGF1R survival signaling in prostate 
cancer (20197463), which both 
complements and counters AR 
antagonistic activity 
Anticancer, growth 
inhibition, via AR 
regulator  
  




   enhanced P38 phosphorelation 
(21615506), P38 activation may 
facilitate androgen-independent AR 
activation (19151763), which counters 






Supplementary Table 4.2: Targets and potency-enhancing molecular interaction modes in 2 fully sub-potent natural product combinations with 









Theapeutic Effect or Response Effect type Synergistic Action for 
Effect or Against Negative 
Response 
Synergy Type 
       
       
aescin (316ug/mL) main 
therapeutic 
component 
158 disrupted membrane after metabolism by 
glycosidases  (1171670), leading to haemolysis 
(21968386) 
haemolysis  thymol affected cell membrane 
structure and enhanced 
permeability by generating 
asymmetries and membrane 
tensions (21660740), thereby 
facilitating the membrane 
insertion or crossing of aescin and 
its subsequent meabolism by 
glycosidases located in the internal 
side of membrane (15340929) 
bioavailability 
enhancement 
thymol  sensitizer  affected cell membrane structure and enhanced 
permeability by generating asymmetries and 




       






343 induced orphan nuclear receptor Nur77 to promote 




   suppresed human telomerase reverse transcriptase 












   induced  Nur77 rexpression (18577687, 21365711) 
may lead to enhanced NFkB activity to reduce 
apoptosis (16082387), and to induce human 
telomerase reverse transcriptase for promoting 




z-ligustilide inhibited NFkB 
(20581853) to counter this 
counteractive action  
anti-counteractive 
action 












Cooperative 347 anticancer mechanism unreported    
z-ligustilide (11.52ug/mL) Cooperative 1.92 anticancer mechanism unreported    
 
Supplementary Table S4.3: Targets and potency-enhancing molecular interaction modes in 9 fully sub-potent natural product combinations with 
potencies of the principal component increased by 10–100 fold. 





Theapeutic Effect or 
Response 
Effect type Synergistic Action for Effect or 
Against Negative Response 





       





14.3 induced haemolysis by 
inserting into and forming 
pores in membrane, and 
alterring  Ca-K and Ca-Mn 
ATPase activities, and these 
activities are enhanced by its 
metabolism by glycosidases 
(19915999) 
haemolysis affected cell membrane structure 
and enhanced permeability of 
anticancer agents by generating 
asymmetries and membrane 
tensions (21660740), thereby 
facilitating membrane insertion or 
crossing of  Quillaja saponins and 
their  subsequent meabolism by 
glycosidases located in the internal 
side of membrane (15340929) 
bioavailability 
enhancement 
       
thymol  sensitizer  affected cell membrane 
structure and enhanced 
permeability by generating 





       
       
Salicylaldehyde (141ug/mL) main 
therapeutic 
component 
>26 inhibited fungal antioxidant 
system proteins cytosolic 
superoxide dismutase, 
mitochondrial SOD and 
glutathione reductase, 
thereby producing antifungal 
antifungal Linalool increased ROS species in 
certain cells by  (19428344), 
which complements 
Salicylaldehyde's inhibition of 







       
Linalool (281ug/mL) Cooperative >78 inhibited mitochondrial 
complexes and increased 
ROS species in certain cells 
by  (19428344), both 
inhibition of mitochondrial 
function and ROS production 
may contribute to antifungal 
activity (16834605, 
20803256) 
antifungal   
       
       
berberine (256ug/mL) main 
therapeutic 
component 
16 inhibited microbial  division 
protein FtsZ to produce 
antimicrobial effect 
(18275156, 21060782) 
antimicrobial   






the mutidrug pump, thereby 
potentiated berberine's 
antimicrobial activity (10677479) 
bioavailability 
enhancement 






sensitizer   potentiation   
       
Linoleic acid (1mg/mL) co-therapeuti
c ingredient 
20 inhibited bacterial enoyl-acyl 
carrier protein reductase 
FabI involved in fatty acid 
synthesis, thereby producing 
antibacterial effect 
(16146629, 21862391) 
Antibacterial   
   effluxed by a farAB-encoded 





Combination of Linoleic acid and 




   resisted by bacterial cell 





       
Oleic acid (1mg/mL) co-therapeuti
c ingredient 
20 inhibited bacterial enoyl-acyl 
carrier protein reductase 
FabI involved in fatty acid 
synthesis, thereby producing 
antibacterial effect 
(16146629, 21862391) 
Antibacterial   
   effluxed by a farAB-encoded 





Combination of Linoleic acid and 







       
       
eriodictyol (0.8mg/mL) main 
therapeutic 
component 
16.7 produced prooxidative DNA 
damage effect (19941260), 
which may contribute to 
antimicrobial activity 
Antimicrobial hesperetin has higher 
bioavailability (20447374) and is 
converted into eriodictyol in 
microbial culture by microbial 
enzymes (21873058), thereby 




hesperetin (1mg/mL) Cooperative 3.33 reduced reducing the activity 
of bacterial enzymes 
(18812032), which may 
contribute to antimicrobial 
activity 
Antimicrobial   
   interacted with membrane 
better, leading to higher 
bioavailability inside cells 
(20447374) 
Bioavailability   
       
       
eriodictyol (0.8mg/mL) main 
therapeutic 
component 
16.7 produced prooxidative DNA 
damage effect (19941260), 
which may contribute to 
antimicrobial activity 
Antimicrobial Naringenin has higher 
bioavailability (2753859, 7603409, 
8132524) and is converted into 
eriodictyol in microbial culture by 






thereby enhancing the 
bioavailability of eriodictyol 
       
Naringenin (1mg/mL) Cooperative 2.5 inhibited  VacA vacuolation 
(15770537) to hinder the 
release of nutrients 
necessary for microbial 
growth and survival 
(12814772), leading to 
antimicrobial activity 
Antimicrobial   
   interacted with membrane 
better (2753859), leading to 
higher bioavailability inside 
cells (7603409, 8132524) 
Bioavailability   
       
       
Berberine (500ug/mL) main 
therapeutic 
component 
16 inhibited microbial  division 
protein FtsZ to produce 
antimicrobial effect 
(18275156, 21060782) 
antimicrobial   





biochanin A inhibited the mutidrug 
pump, thereby potentiated 







       
biochanin A (>312.5ug/mL) Cooperative >31.3 inhibited microbial growth 
(20335979, 21328137) 
antimicrobial   
       
       
Berberine (500ug/mL) main 
therapeutic 
component 
16 inhibited microbial  division 
protein FtsZ to produce 
antimicrobial effect 
(18275156, 21060782) 
antimicrobial   





Genistein inhibited the mutidrug 
pump, thereby potentiated 




       
Genistein (100ug/mL) Cooperative 10 inhibited global synthesis of 
DNA, RNA and proteins, 
leading to antimicrobial 
activity (16328542) 
Antimicrobial   
   stabilized covalent 
topoisomerase II-DNA 
cleavage complex, which 
may contribute to its 






       
       
Berberine (500ug/mL) main 
therapeutic 
component 
16 inhibited microbial  division 
protein FtsZ to produce 
antimicrobial effect 
(18275156, 21060782) 
antimicrobial   





Orobol inhibited the mutidrug 
pump, thereby potentiated 




       
Orobol sensitizer   potentiation   
  
Supplementary Table S4.4: Targets and potency-enhancing molecular interaction modes in 5 fully sub-potent natural product combinations with 
potencies of a non-principal component increased by 10–100 fold. 





Theapeutic Effect or 
Response 
Effect type Synergistic Action for Effect 
or Against Negative 
Response 
Type of  
Synergism 




Vanillin (0.6mg/mL) main 
therapeutic 
ingredient 
8 inhibited CYP53A15 to 
produce antifungal 
effect (18505250) 
Antifungal (+/-)-pinoresinol caused 
damage to  fungal plasma 
membrane(20657496) to 
enhance vanillin's transport 




   polymerized by laccase 











       
4-hydroxy-3-methoxycinnamaldehyde 
(0.4mg/mL) 
Cooperative 2 antifungal mechanism 
unreported 
   
       
(+/-)-pinoresinol (1mg/mL) Cooperative 10 caused damage to  
fungal plasma 
membrane to produce 
antifungal effect 
(20657496) 
Antifungal   
       
       
Vanillin (0.6mg/mL) main 
therapeutic 
3 inhibited CYP53A15 to 
produce antifungal 
Antifungal Scopoletin inhibited fungal 






ingredient effect (18505250) 
   polymerized by laccase 










Scopoletin inhibited fungal 
oxidation of vanillin  to 




       
4-Hydroxy-3-methoxycinnamaldehyde 
(0.4mg/mL) 
Cooperative 4 antifungal mechanism 
unreported 
   
       
Scopoletin (1.5mg/mL) Cooperative 18.8 hindered fungi survival 
or germination, inhibited 
detoxification enzymes 
(15826040) 
Antifungal   
       
       
berberine (125ug/mL) main 
therapeutic 
ingredient 
4.2 inhibited microbial  




















       
chrysosplenol-D  (250ug/mL) Cooperative 10 antimicrobial 
mechanism unreported 
   
       
       
berberine (125ug/mL) main 
therapeutic 
ingredient 
4.2 inhibited microbial  




antimicrobial   





chrysoplenetin inhibited the 






       
chrysoplenetin  (250ug/mL) Cooperative 40 antimicrobial 
mechanism unreported 
   
       




curcumin (3.1uM) main 
therapeutic 
ingredient 
3.1 downregulated Notch1 
and Bcl-xL to inactivate 
NFkB, thereby 
promoting growth 






isoflavone inhibited Notch, 
NFkB and AkT, and activated 
P53(22200028) to 
complement  curcumin's 
action on Notch1 and Bcl-xL 
(16628653), thereby further 
promoting apoptosis  
Complementary 
action 
   activated P38, thereby 
downregulating Bcl2, 
survivin and AkT 




isoflavone inhibited Notch, 
NFkB and AkT, and activated 
P53(22200028) to 
complement  curcumin's 
action on Bcl2, survivin and 
AkT (19676105), thereby 
further promoting apoptosis  
Complementary 
action 
   inhibited AKT-mTOR 







       
isoflavone (183uM) Cooperative 18.3 inhibited Notch, NFkB 
and AkT, and activated 









Supplementary Table 5.1: FDA endorsed mobile apps 
Device Name Applicant 510(k) 
Number 
type measure disease 
AIDERA DIASEND SYSTEM AIDERA AB K101806 data transmitter     




AIRSTRIP OB AIRSTRIP 
TECHNOLOGIES, LP 




AIRSTRIP OB AIRSTRIP 
TECHNOLOGIES, LP 




AIRSTRIP REMOTE PATIENT MONITORING (RPM) AIRSTRIP 
TECHNOLOGIES, LP 
K110503 data viewer     




K112235 data viewer     




K121871 data viewer     
AIRSTRIP REMOTE PATIENT MONITORING (RPM) REMOTE 
DATA VIEWING SOFTWARE, VERSION 3.1 
AIRSTRIP 
TECHNOLOGIES, LP 
K100133 data viewer     
ALIVECOR HEART MONITOR FOR IPHONE ALIVECOR, INC. K122356 monitoring ECG cardiovascular 
ASTHMAPOLIS SYSTEM RECIPROCAL LABS 
CORPORATION 
K121609 medical aid actuations of prescribed MDI usage Anesthesiology 
AVITA BLUETOOTH BLOOD PRESSURE MONITOR, MODEL: 
BPM656ZB 
AVITA CORPORATION K072137 monitoring systolic and diastolic blood pressure; 
pulse rate 
  




DIGITALSYSTEME GMBH MRI  
BEAM BRUSH/BEAM APP BEAM TECHNOLOGIES, 
LLC 
K121165 monitoring brushing usage data tooth decay 
BIOHARNESS ZEPHYR TECHNOLOGY 
CORPORATION 
K113045 monitoring ECG cardiovascular 
BODYGUARDIAN SYSTEM BODYGUARDIAN CONTROL UNIT 
BODYGUARDIAN CONNECT 
PREVENTICE, INC. K121197 monitoring ECG;activity;heart rate; respiration rate cardiovascular 
CARESTREAM PACS CARESTREAM HEALTH, 
INC. 
K110919 data viewer 3D image radiology 





K110499 monitoring ECG cardiovascular 





K081257 monitoring ECG cardiovascular 





K101639 monitoring ECG cardiovascular 
CG-6108 ARRHYTHMIA ECG EVENT RECORDER CARD GUARD 
SCIENTIFIC SURVIVAL, 
LTD. 
K060911 monitoring ECG cardiac arrhythmia 









CONFIDANT 2.5 CONFIDANT INC. K072698 data transmitter     
CUSTOMIZED SOUND THERAPY (CST) TINNITUS OTOSOUND 
PRODUCTS, LLC 
K070599 treatment   Tinnitus 
DASH KNEE BRAINLAB AG K102251 medical aid     
DATEX-OHMEDA S/5 WEB VIEWER, DATEX-OHMEDA S/5 
POCKET VIEWER AND DATEX-OHMEDA S/5 CELLULAR VIEWER 
WITH L-WEB04 SOFTWARE 
GE HEALTHCARE K052975 data viewer real-time patient information   
DIABETESMANAGER SYSTEM, DIABETESMANAGER-RX 
SYSTEM MODEL VERSION 1.1 
WELLDOC, INC K100066 monitoring glucose diabetes 
FREESTYLE TRACKER DIABETES MANAGEMENT SYSTEM ABBOTT DIABETES CARE 
INC. 
K020866 monitoring glucose diabetes 
FREESTYLE TRACKER DIABETES MANAGEMENT SYSTEM ABBOTT DIABETES CARE 
INC. 
K020866 monitoring glucose diabetes 




K102939 monitoring blood pressure cardiovascular 
FULLY AUTOMATIC WIRELESS BLOOD PRESSURE WRIST 
MONITOR 
ANDON HEALTH CO., 
LTD 
K121470 monitoring blood pressure cardiovascular 
GLUCOPHONE BLOOD GLUCOSE TEST SYSTEM, MODEL 
IGM-0025 
INFOPIA CO., LTD K091168 monitoring glucose diabetes 
IBGSTAR BLOOD GLUCOSE MONITORING SYSTEM, IBGSTAR 
DIABETES MANAGER APPLICATION, REV D 
AGAMATRIX INC K103544 monitoring glucose diabetes 
IGLUCOSE SYSTEM POSITIVEID 
CORPORATION 
K111932 monitoring glucose diabetes 




INTUITION TERARECON, INC. K121916 data viewer EBT, CT, PET or MRI image   




K120672 monitoring blood pressure cardivascular 
MEDAPPS REMOTE PATIENT MONITORING, MODEL MA 100 MEDAPPS, INC. K062377 data transmitter     
MEDICALGORITHMICS REAL-TIME ECG MONITOR AND 
ARRHYTHMIA DETECTOR, MODEL POCKETECG 
MEDICALGORITHMICS 
SP Z.O.O. 
K090037 monitoring heart beat, rhythm abnormalities cardivascular 
MOBILE MIM MIM SOFTWARE INC. K103785 data viewer SPECT, PET, CT, and MRI   
MOBILE MIM MIM SOFTWARE INC. K112930 data viewer SPECT, PET, CT, MRI, X-ray and Ultrasound   
MOBILECT VIEWER NEPHOSITY, INC. K123082 data viewer CT, MRI, X-Ray images   
MOBILE-PATIENT VIEWER DATA CRITICAL 
CORPORATION 
K011436 data viewer     
MOBIUS ULTRASOUND IMAGING SYSTEM MOBISANTE, INC. K102153 imaging     
MODIFICATION TO: CG-6108 ACT-3L CONTINUOUS ECG 




K101703 monitoring ECG cardiovascular 
MODIFICATION TO: POCKETVIEW ECG SOFTWARE MICROMEDICAL 
INDUSTRIES, LTD. 
K013311 data viewer ECG cardiovascular 
MYGLUCOHEALTH GLUCOSE MONITORING SYSTEMS ENTRA HEALTH 
SYSTEMS, LTD. 
K081703 monitoring glucose diabetes 
MYVISIONTRACK(TM) VITAL ART AND SCIENCE 
INCORPORATED 
K121738 monitoring central 3 degrees metamorphopsia (visual 
distortion)  
maculopathy 






PANOPTIC WELCH ALLYN, INC. K121405 imaging     
PILL PHONE VOCEL K060298 medical aid drug 
compliance 
    
PIXEL APP GAUSS SURGICAL, INC. K120473 medical aid   surgery 
PIXEL APP GAUSS SURGICAL, INC. K121274 medical aid   surgery 
PROTEUS INGESTION CONFINMATION SYSTEMS PROTEUS BIOMEDICAL, 
INC. 
K113070 monitoring physiological and behavioral metrics 
including heart rate, activity, body angle 
and time-stamped user-logged events 
general 
REKA E100 REKA PTE LTD K111438 monitoring ECG cardiovascular 
RESOLUTIONMD MOBILE 3.1 MODEL RMD-MOB-31 CALGARY SCIENTIFIC, 
INC. 
K123186 data viewer CT and MR medical images   
RESOLUTIONMD MOBILE MODEL RMB-MOB-2X CALGARY SCIENTIFIC, 
INC. 
K111346 data viewer CT and MR medical images   
RHYTHMSTAT XL DATA CRITICAL CORP. K971650 diagnostic ECG cardiovascular 




K041901 monitoring heart beat cardiovascular 
SILHOUETTE, MODEL 1000.01 ARANZ MEDICAL 
LIMITED 
K070426 monitoring external wounds external wounds 
SMARTHEART SHL TELEMEDICINE 
INTERNATIONAL LTD. 
K113514 monitoring 12 
lead EGG and rhythm strip 
cardiovascular 
SPECTRUM AND SPECTRUM WITH MASTER DRUG LIBRARY SIGMA INTL. K042121 medical aid 
administration 
    
SURGICASE CONNECT MATERIALISE N.V. K113599 data transmitter CT and MR medical images cardiovascular 






TM2005 PERSONAL MEDICAL PHONE CENTER CARD GUARD 
SCIENTIFIC SURVIVAL, 
LTD. 
K024365 data viewer ECG, and  
other patient related data, (such as 
demographics, doctors, medical history 
and status, diagnoses, etc.) . 
cardiovascular 
VEO MULTIGAS MONITOR FOR POCKET PC, MODEL 400221 WEISSBURG 
ASSOCIATES 
K051857 monitoring carbon dioxide; oxygen Anesthesiology 
VESTIBULAR ANALYSIS APPARATUS CAPACITY SPORTS, LLC K121590 monitoring balance   
WAVESENSE DIABETES MANAGER MODEL VERSION 1.3.4 AGAMATRIX K101597 data transmitter glucose diabetes 
WEB VIEWER, POCKET VIEWER AND CELLULAR VIEWER WITH 
L- WEB05 SOFTWARE 
GE HEALTHCARE K061994 data viewer     
WELLDOC DIABETES MANAGER SYSTEM AND DIABETES 
MANAGER RX SYSTEM 
WELLDOC, INC K112370 monitoring glucose diabetes 
WELLDOC DIABETES MANAGER SYSTEM AND DIABETES 
MANAGER RX SYSTEM 
WELLDOC, INC K120314 monitoring glucose diabetes 
WITHINGS BLOOD PRESSURE MONITOR WITHINGS K110872 monitoring blood pressure cardiovascular 
WITHINGS, SMART BODY SCALE ZHONGSHAN TRANSTEK 
ELECTRONICS CO., LTD. 
K121971 monitoring weight, BMI, body fat   
 
 
 
